<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000Res</journal-id><journal-id journal-id-type="iso-abbrev">F1000Res</journal-id><journal-id journal-id-type="pmc">F1000Research</journal-id><journal-title-group><journal-title>F1000Research</journal-title></journal-title-group><issn pub-type="epub">2046-1402</issn><publisher><publisher-name>F1000 Research Limited</publisher-name><publisher-loc>London, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12688/f1000research.19197.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Recent advances in understanding dengue</article-title><fn-group content-type="pub-status"><fn><p>[version 1; peer review: 2 approved]</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Halstead</surname><given-names>Scott</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft Preparation</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7818-348X</contrib-id><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><aff id="a1">
<label>1</label>Emeritus Professor, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xlink:href="mailto:halsteads@erols.com">halsteads@erols.com</email></corresp><fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>31</day><month>7</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>F1000 Faculty Rev-1279</elocation-id><history><date date-type="accepted"><day>22</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2019 Halstead S</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="f1000research-8-21037.pdf"/><abstract><p>This is a selective review of recent publications on dengue clinical features, epidemiology, pathogenesis, and vaccine development placed in a context of observations made over the past half century. Four dengue viruses (DENVs) are transmitted by urban cycle mosquitoes causing diseases whose nature and severity are influenced by interacting factors such as virus, age, immune status of the host, and human genetic variability. A phenomenon that controls the kinetics of DENV infection, antibody-dependent enhancement, best explains the correlation of the vascular permeability syndrome with second heterotypic DENV infections and infection in the presence of passively acquired antibodies. Based on growing evidence
<italic>in vivo</italic> and
<italic>in vitro</italic>, the tissue-damaging DENV non-structural protein 1 (NS1) is responsible for most of the pathophysiological features of severe dengue. This review considers the contribution of hemophagocytic histiocytosis syndrome to cases of severe dengue, the role of movement of humans in dengue epidemiology, and modeling and planning control programs and describes a country-wide survey for dengue infections in Bangladesh and efforts to learn what controls the clinical outcome of dengue infections. Progress and problems with three tetravalent live-attenuated vaccines are reviewed. Several research mysteries remain: why is the risk of severe disease during second heterotypic DENV infection so low, why is the onset of vascular permeability correlated with defervescence, and what are the crucial components of protective immunity?</p></abstract><kwd-group kwd-group-type="author"><kwd>dengue</kwd><kwd>flavivirus</kwd><kwd>pathogenesis</kwd><kwd>immunity</kwd><kwd>dengue fever</kwd><kwd>severe dengue</kwd><kwd>vaccines</kwd><kwd>epidemiology</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement></funding-group></article-meta><notes><sec sec-type="editor-note"><title>Editorial Note on the Review Process</title><p>
<ext-link ext-link-type="uri" xlink:href="http://f1000research.com/browse/f1000-faculty-reviews">F1000 Faculty Reviews</ext-link> are commissioned from members of the prestigious
<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty">F1000 Faculty</ext-link> and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).</p><p>The referees who approved this article are: </p><list list-type="simple" list-content="reviewer-list"><list-item><p>
<named-content content-type="reviewer-name">Subhash G Vasudevan</named-content>, Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p></list-item><list-item><p>
<named-content content-type="reviewer-name">Aravinda M de Silva</named-content>, Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p></list-item></list></sec></notes></front><body><sec sec-type="intro"><title>Introduction</title><p>Dengue viruses (DENVs) are relatively new pathogens. Transmission of virus from human to human by the bite of the mosquito
<italic>Aedes aegypti</italic> began around three centuries ago
<sup><xref rid="ref-1" ref-type="bibr">1</xref>,
<xref rid="ref-2" ref-type="bibr">2</xref></sup>. Establishing an urban cycle required three separate emergence events: (a) evolution of a West African tree hole-breeding ancestor into
<italic>Aedes aegypti</italic>, an anthropophilic domestic-breeding sub-species, and transportation of this mosquito (b) to tropical America via the slave trade and (c) in reverse direction to Europe and Asia where each of the four DENVs were introduced into the urban transmission cycle
<sup><xref rid="ref-3" ref-type="bibr">3</xref>,
<xref rid="ref-4" ref-type="bibr">4</xref></sup>. These emergence events in all likelihood were preceded by the circulation of a parental virus in sub-human primates throughout greater Southeast Asia during the Quaternary ice age
<sup><xref rid="ref-5" ref-type="bibr">5</xref></sup>. Oceans rose to isolate populations of dengue-infected sub-human primates on mainland Asia and on the islands of Indonesia and the Philippines
<sup><xref rid="ref-6" ref-type="bibr">6</xref></sup>. Viral evolution did the rest. Now these viruses cause a global pandemic, a consequence of jet airplane distribution of viremic humans throughout a tropical world comprehensively infested by
<italic>Aedes aegypti</italic>
<sup><xref rid="ref-7" ref-type="bibr">7</xref>,
<xref rid="ref-8" ref-type="bibr">8</xref></sup>.</p><p>The world of dengue is massive and its features are constantly changing, as evidenced by the expanding scientific literature. Studies on dengue as an arthropod-borne viral disease contribute to three areas of research: (a) one on mosquito vectors, their bionomics, virus&#x02013;host interactions, epidemiology, and control; (b) a literature on the virus itself; and (c) another describing DENV&#x02013;human interactions. This review is directed to the last of these, focusing on clinical features, epidemiology, pathogenesis, and vaccine development.</p><p>The four DENVs are genetically related and biologically similar. Dengue is not the only human viral pathogen to circulate in biologically or genetically related groups. Many enteroviruses and respiratory viruses exist in groups of closely related pathogens. Although some degree of cross-protection may accompany sequential infections with members of these groups, most such outcomes are not well studied or understood. Dengue differs for researchers, a clear-eyed view of the observed complexity of dengue 1, 2, 3, and 4 (DENV) interactions with humans is crucial. For details of dengue disease features and pathogenesis, see my previous F1000 report
<sup><xref rid="ref-9" ref-type="bibr">9</xref></sup>. Infection with a single virus is followed by up to three outcomes: (1) durable protection against infection with a strain of the same DENV, (2) brief protection against infection or disease with a different dengue serotype, and (3) a breakthrough infection with a different dengue serotype that may result in severe disease
<sup><xref rid="ref-10" ref-type="bibr">10</xref>&#x02013;
<xref rid="ref-12" ref-type="bibr">12</xref></sup>. This last outcome has a unique variant: dengue infection in the presence of passively acquired multitypic dengue antibodies may produce severe disease
<sup><xref rid="ref-13" ref-type="bibr">13</xref></sup>. Severe dengue in infants born to dengue-immune mothers is an important problem where dengue is highly endemic, causing 5% of dengue hospitalizations of children
<sup><xref rid="ref-14" ref-type="bibr">14</xref>&#x02013;
<xref rid="ref-17" ref-type="bibr">17</xref></sup>.</p></sec><sec><title>Clinical responses</title><p>Dengue clinical responses are subject to constraints imposed by infecting virus, epidemiology, human immune status, and human genetic makeup. These are reviewed briefly. Dengue disease severity differs by infection parity. Disease may accompany a first or second dengue infection and is infrequent during a third and absent during a fourth
<sup><xref rid="ref-18" ref-type="bibr">18</xref>&#x02013;
<xref rid="ref-20" ref-type="bibr">20</xref></sup>.</p><sec><title>First infections</title><p>Intuitively, infection should result in a dengue clinical outcome. This is far from being the case. Age and viral type have an impact. In young children, primary dengue 1&#x02013;4 infections are frequently inapparent
<sup><xref rid="ref-21" ref-type="bibr">21</xref>&#x02013;
<xref rid="ref-24" ref-type="bibr">24</xref></sup>. As children age, disease response, particularly after puberty, becomes more adult-like. The infecting dengue type interacting with age also controls disease severity. In adults, primary dengue 1 and 3 infections result in high rates of classic dengue fever but dengue 2 and 4 infections cause milder disease and are often inapparent
<sup><xref rid="ref-12" ref-type="bibr">12</xref>,
<xref rid="ref-25" ref-type="bibr">25</xref></sup>. Primary dengue 2 and 4 infections in children of all ages frequently are inapparent
<sup><xref rid="ref-24" ref-type="bibr">24</xref>,
<xref rid="ref-26" ref-type="bibr">26</xref></sup>. Primary dengue 1 infections in children are modestly severe to the point of requiring hospitalization
<sup><xref rid="ref-26" ref-type="bibr">26</xref></sup>.</p></sec><sec><title>Second infections</title><p>Second heterotypic dengue disease has been observed in 12 sequences
<sup><xref rid="ref-19" ref-type="bibr">19</xref></sup>. In children, overt disease is recognized clinically in perhaps 20 to 30% of second heterotypic dengue infections and severe disease in about 2%
<sup><xref rid="ref-12" ref-type="bibr">12</xref>,
<xref rid="ref-27" ref-type="bibr">27</xref>,
<xref rid="ref-28" ref-type="bibr">28</xref></sup>. A high incidence of severe disease has been reported for infection sequences with DENV1&#x02013;2, 3&#x02013;2, 4&#x02013;2, 1&#x02013;3, and 2&#x02013;1
<sup><xref rid="ref-27" ref-type="bibr">27</xref>,
<xref rid="ref-29" ref-type="bibr">29</xref>&#x02013;
<xref rid="ref-32" ref-type="bibr">32</xref></sup>. The severity of second heterotypic dengue infections is controlled by age at the time of infection and the interval between first and second infections. Owing to their intrinsic risk of severe vascular permeability, young children are at higher risk of fatal outcome with heterotypic DENV infections
<sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>. Exposure to DENV at intervals of less than 2 years may inhibit infection and suppress disease severity
<sup><xref rid="ref-19" ref-type="bibr">19</xref>,
<xref rid="ref-34" ref-type="bibr">34</xref></sup>. Short-term protection and ultimately enhanced second heterotypic DENV infection outcome may be controlled by natural declines or changes in heterotypic antibodies (or both) following a first DENV infection
<sup><xref rid="ref-35" ref-type="bibr">35</xref>,
<xref rid="ref-36" ref-type="bibr">36</xref></sup>. An increase in disease severity was observed when the interval between first and second infections was 20 years as opposed to 4 years
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup>. As an explanation, it was observed that severe disease at a long interval was correlated with an observed steady decrease in heterotypic antibody titers over a long period
<sup><xref rid="ref-37" ref-type="bibr">37</xref>,
<xref rid="ref-38" ref-type="bibr">38</xref></sup>. During secondary dengue infections, adults are at greater risk than children of bleeding whereas children are at greater risk than adults of vascular permeability
<sup><xref rid="ref-39" ref-type="bibr">39</xref></sup>. Human genetic inhomogeneity, particularly across ethnic groups, affects disease expression in a variety of ways
<sup><xref rid="ref-40" ref-type="bibr">40</xref>&#x02013;
<xref rid="ref-43" ref-type="bibr">43</xref></sup>. The most notable genetic effect is the suppression of severe disease accompanying a second heterotypic dengue infection that has been observed in black patients in sub-Saharan Africa and is linked to a gene that regulates cellular dengue infection via lipid metabolism
<sup><xref rid="ref-44" ref-type="bibr">44</xref></sup>. A final pathophysiological constraint during secondary dengue infection is the fact that the onset of vascular permeability is correlated with defervescence. Mechanisms controlling these constraints are not well understood.</p><p>Despite a consensus on the importance of early recognition of the remediable dengue vascular permeability syndrome (DVPS) (fever, thrombocytopenia, abnormal hemostasis, elevated liver enzyme levels, hypoalbuminemia, complement activation, and vascular permeability), there is not wide agreement about how to define dengue disease
<sup><xref rid="ref-45" ref-type="bibr">45</xref></sup>. &#x0201c;Severe dengue&#x0201d; may include life-threatening conditions such as severe bleeding or impaired central nervous system, heart, or kidney functions in the absence of vascular permeability. This wide range of poorly defined and diverse pathophysiological endpoints may impede the early recognition and rapid and accurate assessment of fluid losses to be followed by accurate management of fluid resuscitation. Critically, research to identify pathophysiological mechanisms of the vascular permeability syndrome requires relevant and standardized case definitions
<sup><xref rid="ref-46" ref-type="bibr">46</xref></sup>.</p><p>A literature describing unusual clinical features or outcomes of dengue infections continues to grow at a record pace fueled by the hundreds of thousands of dengue cases that present yearly to sophisticated health-care systems. It is often difficult to place these cases into a pathogenic context because of missing viral, immunological, or epidemiological details (see above). Needed are virus type, age and sex of patients, and infection parity (for example, IgM/IgG ratio) and, if there is a second heterotypic infection, evidence concerning the interval between first and second infections and the identity of first infecting DENV type.</p><p>A subset of severe dengue cases, hemophagocytic lymphohistiocytosis (HLH), is increasingly recognized. HLH, a rare and potentially fatal disorder associated with acute infections, is characterized by fever, pancytopenia, hepatosplenomegaly, and increased serum ferritin. In Puerto Rico, 22 dengue HLH cases, including one death, were detected from 2008 to 2013. Cases were often infants, who frequently had influenza co-infections and were satisfactorily treated with steroids
<sup><xref rid="ref-47" ref-type="bibr">47</xref></sup>. There have been a number of individual case reports of HLH, predominantly from Asia
<sup><xref rid="ref-48" ref-type="bibr">48</xref></sup>. Many of these occurred after prolonged fever
<sup><xref rid="ref-49" ref-type="bibr">49</xref></sup>. An early diagnosis of HLH could deflect from a careful search for vascular permeability and promote the premature use of steroids that have been widely but ineffectively used to treat vascular permeability shock syndrome
<sup><xref rid="ref-50" ref-type="bibr">50</xref></sup>.</p><p>Thrombocytopenia accompanies many dengue infections. The widely used term &#x0201c;dengue hemorrhagic fever&#x0201d; has sensitized doctors and patients alike to the possibility that severe life-threatening bleeding may occur without warning. For this reason, low platelet counts are widely considered to be an indication for the prophylactic administration of platelets. Clinical experts have uniformly advocated against this expensive and potentially dangerous practice
<sup><xref rid="ref-51" ref-type="bibr">51</xref>&#x02013;
<xref rid="ref-54" ref-type="bibr">54</xref></sup>. Investigators in Singapore and Malaysia conducted an open-label, randomized, superiority trial of platelet transfusion and enrolled 372 persons (21 years old or older) with acute laboratory-confirmed dengue with thrombocytopenia (not more than 20,000 platelets per microliter) but no severe or persistent mild bleeding. After enrollment, the subsequent frequency of clinical bleeding was slightly higher (26%) in the transfusion group, 13 of whom had adverse events, than in controls. No deaths were reported
<sup><xref rid="ref-55" ref-type="bibr">55</xref></sup>.</p><p>Progress is being made in identifying and interpreting physiological signals in patients who may progress to shock syndrome. A low echocardiographic stroke volume index and reduced left ventricular function plus high admission venous lactate levels identified dengue patients at high risk of recurrent shock and respiratory distress
<sup><xref rid="ref-56" ref-type="bibr">56</xref></sup>. In 2000, age of 5 to 15 years, a history of vomiting, higher temperature, a palpable liver, and a lower platelet count were risk factors for dengue shock while, during illness, absolute values and rate of daily decline of platelet counts successfully predicted shock
<sup><xref rid="ref-57" ref-type="bibr">57</xref></sup>.</p></sec></sec><sec><title>Epidemiology</title><p>During yellow fever epidemics, it was well understood that multiple cases occurred among members of households but also in persons who visited infested homes. Though less obviously, this same epidemiological feature applies to dengue. Careful prospective studies in the city of Iquitos on the Amazon River in Peru successfully tracked household members throughout the city during DENV transmission seasons
<sup><xref rid="ref-58" ref-type="bibr">58</xref></sup>. For individuals, the risk of DENV infection is controlled by the presence or absence of
<italic>Aedes aegypti</italic> in places visited during the daytime. Risk is not a matter of vector abundance but of vector presence. Individuals increased their estimated transmission rate from 1.3 if they stayed at home to 3.75 when they visited other locations during daytime hours (for example, markets or homes of friends or relatives)
<sup><xref rid="ref-59" ref-type="bibr">59</xref></sup>. DENV is not spread significantly by sick individuals. Those who developed dengue fever spent more time at home, visited fewer locations, and in some cases visited locations closer to home and spent less time at certain types of locations than did individuals who were well
<sup><xref rid="ref-60" ref-type="bibr">60</xref></sup>.</p><p>In highly endemic southern Vietnam and Yogyakarta, a city in Indonesia, mobility data collected from children and young adults via prospective travel diaries found that all ages spent about half of their daytime hours (5 a.m. to 9 p.m.) at home while children under the age of 14 years spent a greater proportion of their time within 500 m of home than did older respondents. Mobility of specific age groups within populations must be taken into consideration in planning dengue preventive interventions
<sup><xref rid="ref-61" ref-type="bibr">61</xref>,
<xref rid="ref-62" ref-type="bibr">62</xref></sup>.</p><p>There is now better understanding of how DENVs successfully maintain transmission when only 20 to 30% of infected persons develop a disease. Studies indicate that silent infections may contribute as much as 84% of total DENV transmission. In persons who do develop dengue disease, most infections of mosquitoes occur prior to the onset of symptoms and only 1% of mosquito infections occur after symptoms have begun
<sup><xref rid="ref-63" ref-type="bibr">63</xref></sup>. The substantial role that inapparent infections play during dengue epidemics may contribute to more rapid transmission and widespread geographic spread of virus, reducing the usefulness of case data to predict where an outbreak will occur and what its final size will be
<sup><xref rid="ref-64" ref-type="bibr">64</xref>,
<xref rid="ref-65" ref-type="bibr">65</xref></sup>.</p><p>The introduction of a new flavivirus, Zika, into the Western Hemisphere in 2015 was the cause of considerable consternation, not simply because of its unexpected linkage to Guillain&#x02013;Barr&#x000e9; syndrome; Zika infection of pregnant women also caused a congenital Zika syndrome in infants. There were additional fears that Zika infections might enhance DENV infections or vice versa. An entirely unsuspected outcome has been that Zika behaves like a highly effective dengue vaccine. The Zika epidemic of 2015 to 2016 was followed by a reduction in clinical dengue cases throughout Latin America from 2,413,693 in 2015 to about 500,000 in both 2017 and 2018, a 77% reduction in dengue cases (Pan American Health Organization data). Similar outcomes were reported from surveillance studies in Salvador, Brazil
<sup><xref rid="ref-66" ref-type="bibr">66</xref>,
<xref rid="ref-67" ref-type="bibr">67</xref></sup>. It is suspected that Zika infection may have served to protect an epidemiologically and clinically important group, monotypic dengue-immunes, responsible for secondary DENV clinical disease
<sup><xref rid="ref-68" ref-type="bibr">68</xref></sup>.</p><p>A mystery in the global dengue pandemic is why, in the mid-20th century, severe dengue was highly endemic in Southeast but not South Asia
<sup><xref rid="ref-69" ref-type="bibr">69</xref></sup>. A remarkable nationwide survey of vector mosquitoes, dengue antibodies, and clinical disease, conducted in Bangladesh, may provide an answer. Out of 97,162 total communities, 70 were randomly selected for visits in 2014 and 2016, and one sixth of households, including 5,866 individuals, were interviewed
<sup><xref rid="ref-70" ref-type="bibr">70</xref></sup>. Many areas of rural Bangladesh were found to be devoid of dengue disease with low prevalence of dengue antibodies and low or no populations of
<italic>Aedes aegypti</italic> and
<italic>Aedes albopictus</italic>. Residents of Dhaka and Chittagong, where a number of recent outbreaks of dengue and chikungunya have occurred, had a high prevalence of dengue antibodies, abundant vector mosquitoes, and disease. A cluster of smaller cities and villages in the Southwestern corner of the country had modest dengue endemicity. The epidemiology of dengue in India may have been similar to that in Bangladesh today but suffered a steady invasion of
<italic>Aedes aegypti</italic> throughout the country and into rural areas. This epidemiological evolution may explain the recent emergence of epidemic severe dengue throughout India.</p><p>The reason why yellow fever continues to be a major health problem in the American tropics is a fateful event that occurred centuries ago: the stable introduction of yellow fever virus into a complex zoonotic cycle
<sup><xref rid="ref-71" ref-type="bibr">71</xref></sup>. All four DENVs circulate as zoonoses in Asia and zoonotic dengue 2 was possibly transplanted from Asia to Africa. Genetic studies suggest that, during the slave trade, the African DENV2 was brought to the American tropics, where it entered the urban cycle
<sup><xref rid="ref-5" ref-type="bibr">5</xref></sup>. But has a dengue zoonotic cycle been established? Only modest efforts have been made to answer this question. A search for a sylvatic DENV cycle was initiated in a forested area of the eastern Amazon near Iquitos, Peru, a city where all four DENVs are endemic. Twenty seronegative Aotus monkeys were kept in jungle locations for a total of 10 years and were bled for virus and for antibody conversions with no evidence of DENV
<sup><xref rid="ref-72" ref-type="bibr">72</xref></sup>.</p></sec><sec><title>Pathogenesis</title><p>Soon after the DVPS was identified, clinical and epidemiological data strongly associated it with second heterotypic DENV infections and also with primary DENV infections of infants born to dengue-immune mothers
<sup><xref rid="ref-11" ref-type="bibr">11</xref>,
<xref rid="ref-73" ref-type="bibr">73</xref></sup>. Pathology studies have consistently demonstrated human DENV infection target cells to be of myeloid lineage
<sup><xref rid="ref-74" ref-type="bibr">74</xref></sup>. When DENV infections occur
<italic>in vitro</italic> or
<italic>in vivo</italic> in the presence of sub-neutralizing dengue antibodies, enhanced infections/disease may result
<sup><xref rid="ref-35" ref-type="bibr">35</xref>,
<xref rid="ref-75" ref-type="bibr">75</xref></sup>. Indeed, the peak of early illness viremias or antigenemia successfully predicted disease severity
<sup><xref rid="ref-26" ref-type="bibr">26</xref>,
<xref rid="ref-76" ref-type="bibr">76</xref>,
<xref rid="ref-77" ref-type="bibr">77</xref></sup>. This phenomenon, antibody-dependent enhancement (ADE) of DENV infection of Fc receptor&#x02013;bearing cells, differs from infection of these same cells in the absence of antibodies by two mechanisms: an increase in the number of cells infected (extrinsic ADE) or an increase in the intracellular production of DENV (intrinsic ADE)
<sup><xref rid="ref-78" ref-type="bibr">78</xref></sup>.</p><p>DENV ADE has been observed in animal models. Second heterotypic DENV2 infections produced enhanced viremia but not vascular permeability in rhesus monkeys
<sup><xref rid="ref-79" ref-type="bibr">79</xref></sup>. Efforts to reliably achieve vascular permeability disease during second heterotypic DENV infections in animals, including mice, have not been successful
<sup><xref rid="ref-80" ref-type="bibr">80</xref></sup>. When DENV antibodies were passively transferred to rhesus monkeys prior to infection with DENV2, enhanced viremias were observed but without vascular permeability. Administration of monoclonal or polyclonal dengue antibodies to mice has regularly resulted in enhanced DENV infections accompanied by vascular permeability and other features of DVPS
<sup><xref rid="ref-81" ref-type="bibr">81</xref></sup>. Also, it has been possible to produce vascular permeability in DENV-infected infant mice born to dengue-immune mothers
<sup><xref rid="ref-82" ref-type="bibr">82</xref></sup>. But other hypotheses of severe dengue pathogenesis that attribute disease (1) to a weakened ability of secondary T cells to contain DENV infection because of the original antigenic sin phenomenon, (2) to the hyper-production of endothelium-damaging secondary infection T-cell cytokines and chemokines, (3) to the DENV non-structural protein 1 (NS1) heterophile antibodies raised during first DENV infections that damage platelets, endothelial cells, or blood clotting proteins during second infections, or (4) to the ability of dengue IgG immune complexes to stimulate mast cells to release vasoactive amines fail to satisfy the requirements of Occam&#x02019;s razor
<sup><xref rid="ref-83" ref-type="bibr">83</xref>&#x02013;
<xref rid="ref-86" ref-type="bibr">86</xref></sup>. None of these hypotheses explains the phenomenon of infant DVPS where B- and T-cell responses are primary and anti-DENV or anti-NS1 IgG antibody concentrations at the onset of illness are absent or very low.</p><p>ADE is a kinetic force of infection but by itself is not a direct cause of pathology. Recent work in several laboratories has uncovered a pathogen that mediates DVPS with enhanced infections that occur with actively or passively acquired dengue antibodies. It was long known that fatal DENV infections of mice could be prevented by anti-NS1
<sup><xref rid="ref-87" ref-type="bibr">87</xref></sup>. NS1 is produced during all four DENV infections as well as those of other pathogenic flaviviruses
<sup><xref rid="ref-88" ref-type="bibr">88</xref></sup>. Instead of remaining cell-bound, dengue NS1 is released as a hexamer circulating in great quantities in acute-phase blood
<sup><xref rid="ref-89" ref-type="bibr">89</xref></sup>. A perceptive study, published in 2006, suggested that the high levels of circulating NS1 documented in patients with severe dengue might activate complement to mediate vascular permeability
<sup><xref rid="ref-90" ref-type="bibr">90</xref></sup>. Dengue NS1 has been shown to activate complement by the alternative pathway, target liver cells promoting intracellular DENV infection, complex with thrombin in acute-phase blood of severe dengue, activate platelets
<italic>in vitro</italic> via Toll-like-receptor 4 (TLR4), and produce thrombocytopenia in TLR4 knockout and normal mice
<sup><xref rid="ref-90" ref-type="bibr">90</xref>&#x02013;
<xref rid="ref-93" ref-type="bibr">93</xref></sup>. In 2015, an analogy between the cellular biology of bacterial lipopolysaccharides (LPSs) and that of DENV NS1 was discovered
<sup><xref rid="ref-94" ref-type="bibr">94</xref></sup>. Each interacts with TLR4 on the surface of monocytes, macrophages, and endothelial cells, inducing the release of a range of cytokines and chemokines. Some of these same cytokines and chemokines have been found in the blood of patients accompanying DVPS.
<italic>In vitro</italic>, NS1 disrupted endothelial cell monolayer integrity. The authors concluded that DVPS was a viral protein toxicosis. NS1-mediated cytokine release could be inhibited by the TLR4 antagonist LPS&#x02013;
<italic>Rhodobacter sphaeroides</italic>, suggesting an avenue for therapeutic intervention.</p><p>Crucially, the same observation was confirmed in an
<italic>in vivo</italic> model
<sup><xref rid="ref-95" ref-type="bibr">95</xref></sup>. DENV2 NS1 inoculated intravenously at physiologically relevant concentrations in sub-lethally DENV2-infected C57BL/6 mice resulted in lethal vascular permeability. Vaccination of mice with DENV2 NS1 protected them against endothelial leakage and death from lethal DENV2 challenge. Mice immunized with all four DENV NS1 proteins were completely protected against homologous DENV challenges, whereas immunization with DENV1 NS1 partially protected against heterologous DENV2 challenge. Furthermore, DENV NS1 was shown to directly alter the barrier function of pulmonary endothelial cell monolayers through disruption of the endothelial glycocalyx-like layer (EGL) by triggering the activation of endothelial sialidases, cathepsin L, and heparanase, enzymes responsible for degrading sialic acid and heparan sulfate proteoglycans
<sup><xref rid="ref-96" ref-type="bibr">96</xref></sup>. Separately, disruption of endothelial glycocalyx components had been shown to correlate with plasma leakage during severe DENV infection in humans
<sup><xref rid="ref-97" ref-type="bibr">97</xref>,
<xref rid="ref-98" ref-type="bibr">98</xref></sup>. More recently, the contribution of these DENV NS1-induced endothelial cell&#x02013;intrinsic pathways to NS1-mediated vascular leakage was demonstrated to be independent of inflammatory cytokines but dependent on the integrity of endothelial glycocalyx components both
<italic>in vitro</italic> and
<italic>in vivo</italic>
<sup><xref rid="ref-99" ref-type="bibr">99</xref></sup>. A DENV NS1 vaccine is taking shape
<sup><xref rid="ref-100" ref-type="bibr">100</xref></sup>. In conclusion, NS1 toxicosis is demonstrably an efferent mechanism of vascular permeability in mice and is controlled by DENV production in cells and, in turn, by ADE
<sup><xref rid="ref-88" ref-type="bibr">88</xref></sup>.</p><p>As described, DVPS is a rare outcome of a second heterotypic DENV infection. Identifying those at risk and understanding why they develop overt versus silent infections continue to be focuses of research. In a long-standing children&#x02019;s cohort in Kamphaeng Phet, Thailand, peripheral blood mononuclear cells (PBMCs) were collected from children prior to their experiencing second heterotypic DENV infections, whether overt or silent. Cultured pre-infection PBMCs were stimulated with DENV1&#x02013;4 antigens. Of 30 cytokines or chemokines studied, six had elevated responses in children who experienced silent second DENV infections and three had elevated responses in children who developed symptoms during a subsequent DENV infection. Significant differences were found in cytokine production based on both the type of DENV used for stimulation and the occurrence of clinical illness. Secretion of interleukin 15 (IL-15) and monocyte chemotactic protein 1 (MCP-1) was significantly higher by PBMCs of subjects who later developed symptomatic DENV infection. These studies are beginning to show how genetic and metabolic phenomena differing between individuals may control infectious processes and host responses
<sup><xref rid="ref-101" ref-type="bibr">101</xref></sup>.</p></sec><sec><title>Vaccines</title><sec><title>Dengvaxia</title><p>The most advanced dengue vaccine is a chimera of structural genes of the four DENVs with the yellow fever vaccine non-structural genome. This vaccine was tested for vaccine efficacy and safety in placebo-controlled clinical trials enrolling 35,000 children (2 to 16 years old) in 10 dengue-endemic countries
<sup><xref rid="ref-102" ref-type="bibr">102</xref></sup>. Efficacy results were mixed. Through year 3 after the first dose, vaccine protection against hospitalization of children at least 9 years old was 65.5% but among children 8 years old or younger was 44.6%
<sup><xref rid="ref-102" ref-type="bibr">102</xref></sup>. In the 2- to 5-year-old age group, vaccinated children were hospitalized five times more frequently than those in the placebo group. Among the 11% of children whose serostatus (when vaccinated) was known, protection in seronegative children 8 years old or younger was 14.4% but in those 9 years old or older was 52.5%. These data led the manufacturer and expert committees to recommend that vaccine be restricted to children 9 years old or older
<sup><xref rid="ref-102" ref-type="bibr">102</xref>,
<xref rid="ref-103" ref-type="bibr">103</xref></sup>. A new serological test made it possible to distinguish those who were seronegative from those who were dengue-immune at the time of vaccination
<sup><xref rid="ref-104" ref-type="bibr">104</xref></sup>. When this test was applied to sera from a 10% randomized cohort of phase 3 children, dengue seronegativity rather than age controlled risk to severe hospitalized dengue disease (platelet count of less than 100,000 mm
<sup>3 </sup>evidence of vascular permeability) over the period 5 to 6 years after first dose in children given vaccine
<sup><xref rid="ref-105" ref-type="bibr">105</xref></sup>. With this evidence of declining efficacy, the World Health Organization (WHO) Scientific Advisory Group of Experts, the Global Advisory Committee on Vaccine Safety, and the WHO Dengue Vaccine Working Group in 2016 recommended that vaccine be given to individuals with known past dengue infection or to populations with 80% DENV seroprevalence
<sup><xref rid="ref-106" ref-type="bibr">106</xref></sup>.</p><p>Why did Dengvaxia fail to protect seronegative children? When vaccinated children developed dengue disease despite circulating tetravalent DENV neutralizing antibodies, this provided solid evidence that conventionally measured human neutralizing antibodies were not protective
<sup><xref rid="ref-102" ref-type="bibr">102</xref>,
<xref rid="ref-107" ref-type="bibr">107</xref>&#x02013;
<xref rid="ref-110" ref-type="bibr">110</xref></sup>. New observations suggest that it may be necessary to redefine the design of classic neutralization tests. When live DENV1 virus recovered from humans during the acute phase of a dengue infection was used to measure neutralization by antibodies, this virus was neutralized only by homotypic antibodies. By contrast, DENV1 grown in C6/36 or Vero tissue cultures was highly neutralized by homotypic and heterotypic dengue antibodies. Why? DENV1 grown in humans was found to be fully mature and 50- to 700-fold more infectious in cell culture than virus harvested after one passage in C6/36 or Vero cells. Human plasma and cell culture&#x02013;derived DENV1 virions had identical genome sequences, indicating that differences in the neutralization of virus were attributable to the maturation state
<sup><xref rid="ref-111" ref-type="bibr">111</xref></sup>. Might DENV maturation status affect biological outcomes of DENV&#x02013;antibody interactions, such as heterotypic protection or ADE?</p><p>Another explanation for Dengvaxia protection failure is that antibodies raised by vaccine may be poorly matched to the specific DENV genotypes in circulation. Two groups found genetic differences in the DENVs recovered during the first 25 months after first dose from placebos or vaccinated children
<sup><xref rid="ref-112" ref-type="bibr">112</xref>,
<xref rid="ref-113" ref-type="bibr">113</xref></sup>. The DENV4 in the Sanofi vaccine is genotype II. Genotype I (GI) and genotype II (GII) DENVs were both circulating in Asia during the vaccine trial. Both groups found vaccine efficacy to be higher against GII (83%) compared with GI (47%) DENV4s. In fact, Juraska and colleagues demonstrated that variations at three positions on the envelope protein of DENV4 are strongly correlated with vaccine efficacy
<sup><xref rid="ref-112" ref-type="bibr">112</xref></sup>. These three amino acid positions map to a region on E protein recognized by strongly neutralizing antibodies in people who have been infected with DENV4
<sup><xref rid="ref-114" ref-type="bibr">114</xref></sup>. Indeed, another study recently demonstrated large differences in the ability of sera from na&#x000ef;ve subjects who received the National Institutes of Health dengue vaccine (also based on a DENV4 GII envelope) to neutralize different genotypes of DENV4
<sup><xref rid="ref-115" ref-type="bibr">115</xref></sup>. When Dengvaxia data were stratified by age, the effect was stronger in younger than older children
<sup><xref rid="ref-112" ref-type="bibr">112</xref></sup>. In children 2 to 8 years old, vaccine efficacy against GII viruses was 76.3% whereas efficacy against GI viruses was only 23.9%. In older children (9 to 14 years old), the vaccine was highly efficacious against both GII (89.8%) and GI (85.5%) viruses. The observation that older children who received the Sanofi vaccine were equally protected against DENV4 GI and GII viruses is best explained by the fact that most of these children had immunity to DENVs before vaccination. In this population, the vaccine stimulates strongly cross-neutralizing and cross-protective antibodies analogous to antibodies that develop after natural second DENV infections with a heterologous serotype
<sup><xref rid="ref-116" ref-type="bibr">116</xref></sup>. These antibodies, which target conserved epitopes between serotypes, are unlikely to be influenced by subtle differences between genotypes. In people with no pre-existing immunity to DENVs, current vaccination strategies rely on the ability to induce serotype-specific protection. However, Dengvaxia protection is not durable. Indeed, over the period of 5 to 6 years after first dose, children 2 to 8 years old, vaccinated when seronegative, were not protected but neither did they experience enhanced DENV4 disease
<sup><xref rid="ref-105" ref-type="bibr">105</xref></sup>. It is known that Dengvaxia raises DENV4 type-specific neutralizing antibodies in seronegative persons
<sup><xref rid="ref-116" ref-type="bibr">116</xref></sup>. Perhaps, early after vaccination, DENV4 GI antibodies circulate at levels that protect against vaccine-matched GII but not the mismatched GI strains.</p><p>Another issue is that T-cell immunity may be crucial to durable protection. Studies on dengue-immune humans in Sri Lanka found that multifunctional CD8
<sup>+</sup> T-cell responses were correlated with protection from DENV disease
<sup><xref rid="ref-117" ref-type="bibr">117</xref></sup>. Functional CD8
<sup>+</sup> T-cell responses were directed at a distinct pattern of non-structural protein antigens
<sup><xref rid="ref-118" ref-type="bibr">118</xref></sup>. There is growing evidence that human T-cell responses directed at epitopes on non-structural proteins contribute importantly to homotypic and heterotypic DENV protective immunity
<sup><xref rid="ref-118" ref-type="bibr">118</xref>,
<xref rid="ref-119" ref-type="bibr">119</xref></sup>. These observations were extended to human CD4
<sup>+</sup> T cells that are primed by DENV capsid, NS3 and NS5 antigens
<sup><xref rid="ref-120" ref-type="bibr">120</xref>,
<xref rid="ref-121" ref-type="bibr">121</xref></sup>. CD4
<sup>+</sup> and CD8
<sup>+</sup> T cells raised after a single dose of a tetravalent live-attenuated dengue vaccine were directed to the same repertoire of non-structural protein antigens as T cells from naturally infected humans
<sup><xref rid="ref-122" ref-type="bibr">122</xref>,
<xref rid="ref-123" ref-type="bibr">123</xref></sup>. A high frequency of CD107a
<sup>+</sup> IFN-&#x003b3;
<sup>+</sup> CD8
<sup>+</sup> T cells raised in A 129 mice immunized with DENV2 PDK53 live-attenuated vaccine mediated efficient viral clearance and superior protection against wild-type DENV challenge
<sup><xref rid="ref-124" ref-type="bibr">124</xref></sup>. Dengvaxia does not present non-structural DENV proteins to the immune system. Might this absence contribute to the ineffective vaccine protection of seronegatives?</p></sec><sec><title>TAK 003</title><p>In January 2018, the Takeda Pharmaceutical Company (Tokyo, Japan) announced the completion of phase 3 trials for TAK 003
<sup><xref rid="ref-125" ref-type="bibr">125</xref>&#x02013;
<xref rid="ref-128" ref-type="bibr">128</xref></sup>. Efficacy and safety data for this vaccine have not yet been published (
<ext-link ext-link-type="uri" xlink:href="https://www.takeda.com/newsroom/newsreleases/2019/takedas-dengue-vaccine-candidate-meets-primary-endpoint-in-pivotal-phase-3-efficacy-trial/">https://www.takeda.com/newsroom/newsreleases/2019/takedas-dengue-vaccine-candidate-meets-primary-endpoint-in-pivotal-phase-3-efficacy-trial/</ext-link>). The vaccine consists of a live-attenuated DENV2 strain and three chimeric viruses containing the prM and E protein genes of DENV1, 3, and 4 expressed on the backbone of the DENV2 genome
<sup><xref rid="ref-129" ref-type="bibr">129</xref>,
<xref rid="ref-130" ref-type="bibr">130</xref></sup>. Of these four viruses, one is a successful vaccine candidate, DENV2 16881 PDK 53. This virus achieved exceptionally high rates of seroconversions in seronegative human volunteers with minimal dengue signs or symptoms
<sup><xref rid="ref-131" ref-type="bibr">131</xref></sup>. Attenuating mutations for all four DENVs were identified, and infectious cDNA clones constructed
<sup><xref rid="ref-132" ref-type="bibr">132</xref>,
<xref rid="ref-133" ref-type="bibr">133</xref></sup>. The vaccine also includes structural DENV1, 3, and 4 proteins expressed on a DENV2 backbone. The developers hope for successful protection against all DENV infection/disease on the basis of the broad neutralizing antibody responses that follow two doses of TAK 003. Publication of clinical data from phase 3 clinical trials is awaited with interest.</p></sec><sec><title>Live-attenuated tetravalent dengue vaccine</title><p>There is good dengue vaccine news. For nearly 20 years, the National Institute of Allergy and Infectious Diseases and the Johns Hopkins Bloomberg School of Public Health have designed and tested dengue vaccine candidates. Some were attenuated by removing nucleotides from the non-translated region of the dengue genome. A crucial component of this development program was testing monovalent vaccine candidates for immunogenicity and attenuation in seronegative human volunteers
<sup><xref rid="ref-134" ref-type="bibr">134</xref></sup>. A final product, the live-attenuated tetravalent dengue vaccine (LATV), consists of mutated DENV 1, 3 and 4 and a chimera of structural DENV 2 on a DENV 4 backbone
<sup><xref rid="ref-135" ref-type="bibr">135</xref>&#x02013;
<xref rid="ref-137" ref-type="bibr">137</xref></sup>. Following a single dose of LATV, volunteers were solidly protected from viremia, dengue symptoms, or anamnestic antibody responses after challenge with non-parental wild strains of live DENV2 (Tonga 74) or 3 (Sleman 78)
<sup><xref rid="ref-138" ref-type="bibr">138</xref></sup> (Dr. Anna Durbin, personal communication, April 4, 2019). That this protection is likely to be of long duration is evidenced by the solid immune response observed to a booster dose of live-attenuated vaccine given 12 months after initial dose
<sup><xref rid="ref-139" ref-type="bibr">139</xref></sup>. Protection results are complemented by evidence that a single dose of LATV raises monospecific neutralizing antibodies that are conformationally similar to antibodies raised after human infections with wild-type DENVs that correlate with protection
<sup><xref rid="ref-140" ref-type="bibr">140</xref>&#x02013;
<xref rid="ref-142" ref-type="bibr">142</xref></sup>. Moreover, the T-cell responses to LATV closely resemble those raised after infections with wild-type DENVs
<sup><xref rid="ref-122" ref-type="bibr">122</xref>,
<xref rid="ref-123" ref-type="bibr">123</xref></sup>. Finally, LATV contains genes for three of the four DENV NS1 proteins. LATV is in the third year of phase 3 clinical testing in Brazil. The rate of accruing dengue vaccine efficacy data has been delayed because of an 80% reduction of DENV cases following the Zika virus epidemic of 2016&#x02013;17 in Brazil
<sup><xref rid="ref-143" ref-type="bibr">143</xref></sup>. The outlook for LATV, based on phase 2 clinical trials in humans, is that a single dose of this vaccine will raise durable and solid protection against dengue infections in both seronegatives and seropositives.</p></sec></sec></body><back><ref-list><ref id="ref-1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasilakis</surname><given-names>N</given-names></name><name><surname>Shell</surname><given-names>EJ</given-names></name><name><surname>Fokam</surname><given-names>EB</given-names></name><etal/></person-group>:
<article-title>Potential of ancestral sylvatic dengue-2 viruses to re-emerge.</article-title>
<source><italic toggle="yes">Virology.</italic></source>
<year>2007</year>;<volume>358</volume>(<issue>2</issue>):<fpage>402</fpage>&#x02013;<lpage>12</lpage>.
<pub-id pub-id-type="doi">10.1016/j.virol.2006.08.049</pub-id>
<!--<pub-id pub-id-type="pmcid">3608925</pub-id>-->
<?supplied-pmid 17014880?><pub-id pub-id-type="pmid">17014880</pub-id></mixed-citation></ref><ref id="ref-2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pollett</surname><given-names>S</given-names></name><name><surname>Melendrez</surname><given-names>MC</given-names></name><name><surname>Maljkovic Berry</surname><given-names>I</given-names></name><etal/></person-group>:
<article-title>Understanding dengue virus evolution to support epidemic surveillance and counter-measure development.</article-title>
<source><italic toggle="yes">Infect Genet Evol.</italic></source>
<year>2018</year>;<volume>62</volume>:<fpage>279</fpage>&#x02013;<lpage>295</lpage>.
<pub-id pub-id-type="doi">10.1016/j.meegid.2018.04.032</pub-id>
<!--<pub-id pub-id-type="pmcid">6396301</pub-id>-->
<?supplied-pmid 29704626?><pub-id pub-id-type="pmid">29704626</pub-id></mixed-citation></ref><ref id="ref-3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Powell</surname><given-names>JR</given-names></name><name><surname>Gloria-Soria</surname><given-names>A</given-names></name><name><surname>Kotsakiozi</surname><given-names>P</given-names></name></person-group>:
<article-title>Recent History of
<italic>Aedes aegypti</italic>: Vector Genomics and Epidemiology Records.</article-title>
<source><italic toggle="yes">BioScience.</italic></source>
<year>2018</year>;<volume>68</volume>(<issue>11</issue>):<fpage>854</fpage>&#x02013;<lpage>860</lpage>.
<pub-id pub-id-type="doi">10.1093/biosci/biy119</pub-id>
<!--<pub-id pub-id-type="pmcid">6238964</pub-id>-->
<?supplied-pmid 30464351?><pub-id pub-id-type="pmid">30464351</pub-id></mixed-citation></ref><ref id="ref-4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>MUG</given-names></name><name><surname>Reiner</surname><given-names>RC</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><etal/></person-group>:
<article-title>Past and future spread of the arbovirus vectors
<italic>Aedes aegypti</italic> and
<italic>Aedes albopictus</italic>.</article-title>
<source><italic toggle="yes">Nat Microbiol.</italic></source>
<year>2019</year>;<volume>4</volume>(<issue>5</issue>):<fpage>854</fpage>&#x02013;<lpage>863</lpage>.
<pub-id pub-id-type="doi">10.1038/s41564-019-0376-y</pub-id>
<!--<pub-id pub-id-type="pmcid">6522366</pub-id>-->
<?supplied-pmid 30833735?><pub-id pub-id-type="pmid">30833735</pub-id></mixed-citation></ref><ref id="ref-5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Vasilakis</surname><given-names>N</given-names></name></person-group>:
<article-title>Dengue--quo tu et quo vadis?</article-title>
<source><italic toggle="yes">Viruses.</italic></source>
<year>2011</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1562</fpage>&#x02013;<lpage>608</lpage>.
<pub-id pub-id-type="doi">10.3390/v3091562</pub-id>
<!--<pub-id pub-id-type="pmcid">3187692</pub-id>-->
<?supplied-pmid 21994796?><pub-id pub-id-type="pmid">21994796</pub-id></mixed-citation></ref><ref id="ref-6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasilakis</surname><given-names>N</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name></person-group>:
<article-title>The history and evolution of human dengue emergence.</article-title>
<source><italic toggle="yes">Adv Virus Res.</italic></source>
<year>2008</year>;<volume>72</volume>:<fpage>1</fpage>&#x02013;<lpage>76</lpage>.
<pub-id pub-id-type="doi">10.1016/S0065-3527(08)00401-6</pub-id>
<?supplied-pmid 19081488?><pub-id pub-id-type="pmid">19081488</pub-id></mixed-citation></ref><ref id="ref-7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>S</given-names></name><name><surname>Gething</surname><given-names>PW</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><etal/></person-group>:
<article-title>The global distribution and burden of dengue.</article-title>
<source><italic toggle="yes">Nature.</italic></source>
<year>2013</year>;<volume>496</volume>(<issue>7446</issue>):<fpage>504</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/nature12060</pub-id>
<!--<pub-id pub-id-type="pmcid">3651993</pub-id>-->
<?supplied-pmid 23563266?><pub-id pub-id-type="pmid">23563266</pub-id></mixed-citation></ref><ref id="ref-8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Johansson</surname><given-names>MA</given-names></name><name><surname>Guerra</surname><given-names>CA</given-names></name><etal/></person-group>:
<article-title>Modelling adult
<italic>Aedes aegypti</italic> and
<italic>Aedes albopictus</italic> survival at different temperatures in laboratory and field settings.</article-title>
<source><italic toggle="yes">Parasit Vectors.</italic></source>
<year>2013</year>;<volume>6</volume>:<fpage>351</fpage>.
<pub-id pub-id-type="doi">10.1186/1756-3305-6-351</pub-id>
<!--<pub-id pub-id-type="pmcid">3867219</pub-id>-->
<?supplied-pmid 24330720?><pub-id pub-id-type="pmid">24330720</pub-id></mixed-citation></ref><ref id="ref-9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group>:
<article-title>Pathogenesis of Dengue: Dawn of a New Era [version 1; peer review: 3 approved].</article-title>
<source><italic toggle="yes">F1000Res.</italic></source>
<year>2015</year>;<volume>4</volume>: pii: F1000 Faculty Rev-1353.
<pub-id pub-id-type="doi">10.12688/f1000research.7024.1</pub-id>
<!--<pub-id pub-id-type="pmcid">4754012</pub-id>-->
<?supplied-pmid 26918141?><pub-id pub-id-type="pmid">26918141</pub-id></mixed-citation></ref><ref id="ref-10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sabin</surname><given-names>AB</given-names></name></person-group>:
<article-title>Research on dengue during World War II.</article-title>
<source><italic toggle="yes">Am J Trop Med Hyg.</italic></source>
<year>1952</year>;<volume>1</volume>(<issue>1</issue>):<fpage>30</fpage>&#x02013;<lpage>50</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.1952.1.30</pub-id>
<?supplied-pmid 14903434?><pub-id pub-id-type="pmid">14903434</pub-id></mixed-citation></ref><ref id="ref-11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nimmannitya</surname><given-names>S</given-names></name><name><surname>Halstead</surname><given-names>SB</given-names></name><name><surname>Cohen</surname><given-names>SN</given-names></name><etal/></person-group>:
<article-title>Dengue and chikungunya virus infection in man in Thailand, 1962-1964. I. Observations on hospitalized patients with hemorrhagic fever.</article-title>
<source><italic toggle="yes">Am J Trop Med Hyg.</italic></source>
<year>1969</year>;<volume>18</volume>(<issue>6</issue>):<fpage>954</fpage>&#x02013;<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.1969.18.954</pub-id>
<?supplied-pmid 5355242?><pub-id pub-id-type="pmid">5355242</pub-id></mixed-citation></ref><ref id="ref-12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grange</surname><given-names>L</given-names></name><name><surname>Simon-Loriere</surname><given-names>E</given-names></name><name><surname>Sakuntabhai</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections.</article-title>
<source><italic toggle="yes">Front Immunol.</italic></source>
<year>2014</year>;<volume>5</volume>:<fpage>280</fpage>.
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00280</pub-id>
<!--<pub-id pub-id-type="pmcid">4052743</pub-id>-->
<?supplied-pmid 24966859?><pub-id pub-id-type="pmid">24966859</pub-id></mixed-citation></ref><ref id="ref-13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group>:
<article-title>Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion.</article-title>
<source><italic toggle="yes">Yale J Biol Med.</italic></source>
<year>1970</year>;<volume>42</volume>:<fpage>350</fpage>&#x02013;<lpage>62</lpage>.
<!--<pub-id pub-id-type="pmcid">2591710</pub-id>-->
<?supplied-pmid 5419208?><pub-id pub-id-type="pmid">5419208</pub-id></mixed-citation></ref><ref id="ref-14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name><name><surname>Lan</surname><given-names>NT</given-names></name><name><surname>Myint</surname><given-names>TT</given-names></name><etal/></person-group>:
<article-title>Dengue hemorrhagic fever in infants: research opportunities ignored.</article-title>
<source><italic toggle="yes">Emerg Infect Dis.</italic></source>
<year>2002</year>;<volume>8</volume>(<issue>12</issue>):<fpage>1474</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.3201/eid0812.020170</pub-id>
<!--<pub-id pub-id-type="pmcid">2738509</pub-id>-->
<?supplied-pmid 12498666?><pub-id pub-id-type="pmid">12498666</pub-id></mixed-citation></ref><ref id="ref-15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chau</surname><given-names>TN</given-names></name><name><surname>Quyen</surname><given-names>NT</given-names></name><name><surname>Thuy</surname><given-names>TT</given-names></name><etal/></person-group>:
<article-title>Dengue in Vietnamese infants--results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2008</year>;<volume>198</volume>(<issue>4</issue>):<fpage>516</fpage>&#x02013;<lpage>24</lpage>.
<pub-id pub-id-type="doi">10.1086/590117</pub-id>
<!--<pub-id pub-id-type="pmcid">2730540</pub-id>-->
<?supplied-pmid 18598189?><pub-id pub-id-type="pmid">18598189</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1160637">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chau</surname><given-names>TN</given-names></name><name><surname>Anders</surname><given-names>KL</given-names></name><name><surname>Le Lien</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Clinical and virological features of Dengue in Vietnamese infants.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2010</year>;<volume>4</volume>(<issue>4</issue>):<fpage>e657</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0000657</pub-id>
<!--<pub-id pub-id-type="pmcid">2854125</pub-id>-->
<?supplied-pmid 20405057?><pub-id pub-id-type="pmid">20405057</pub-id></mixed-citation></ref><ref id="ref-17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clapham</surname><given-names>H</given-names></name><name><surname>Cummings</surname><given-names>DA</given-names></name><name><surname>Nisalak</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2015</year>;<volume>9</volume>(<issue>12</issue>):<fpage>e0004262</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0004262</pub-id>
<!--<pub-id pub-id-type="pmcid">4684242</pub-id>-->
<?supplied-pmid 26658730?><pub-id pub-id-type="pmid">26658730</pub-id></mixed-citation></ref><ref id="ref-18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gibbons</surname><given-names>RV</given-names></name><name><surname>Kalanarooj</surname><given-names>S</given-names></name><name><surname>Jarman</surname><given-names>RG</given-names></name><etal/></person-group>:
<article-title>Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.</article-title>
<source><italic toggle="yes">Am J Trop Med Hyg.</italic></source>
<year>2007</year>;<volume>77</volume>(<issue>5</issue>):<fpage>910</fpage>&#x02013;<lpage>3</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.2007.77.910</pub-id>
<?supplied-pmid 17984352?><pub-id pub-id-type="pmid">17984352</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1097345">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhoomiboonchoo</surname><given-names>P</given-names></name><name><surname>Nisalak</surname><given-names>A</given-names></name><name><surname>Chansatiporn</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010.</article-title>
<source><italic toggle="yes">BMC Public Health.</italic></source>
<year>2015</year>;<volume>15</volume>:<fpage>250</fpage>.
<pub-id pub-id-type="doi">10.1186/s12889-015-1590-z</pub-id>
<!--<pub-id pub-id-type="pmcid">4371716</pub-id>-->
<?supplied-pmid 25886528?><pub-id pub-id-type="pmid">25886528</pub-id></mixed-citation></ref><ref id="ref-20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nisalak</surname><given-names>A</given-names></name><name><surname>Lessler</surname><given-names>JT</given-names></name><name><surname>Klungthong</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Forty Years of Dengue Surveillance at a Tertiary Pediatric Hospital in Bangkok, Thailand, 1973-2012.</article-title>
<source><italic toggle="yes">Am J Trop Med Hyg.</italic></source>
<year>2016</year>;<volume>94</volume>(<issue>6</issue>):<fpage>1342</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.15-0337</pub-id>
<!--<pub-id pub-id-type="pmcid">4889755</pub-id>-->
<?supplied-pmid 27022151?><pub-id pub-id-type="pmid">27022151</pub-id></mixed-citation></ref><ref id="ref-21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoon</surname><given-names>IK</given-names></name><name><surname>Srikiatkhachorn</surname><given-names>A</given-names></name><name><surname>Hermann</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Characteristics of mild dengue virus infection in Thai children.</article-title>
<source><italic toggle="yes">Am J Trop Med Hyg.</italic></source>
<year>2013</year>;<volume>89</volume>(<issue>6</issue>):<fpage>1081</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.13-0424</pub-id>
<!--<pub-id pub-id-type="pmcid">3854884</pub-id>-->
<?supplied-pmid 24127167?><pub-id pub-id-type="pmid">24127167</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718144509">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoon</surname><given-names>IK</given-names></name><name><surname>Rothman</surname><given-names>AL</given-names></name><name><surname>Tannitisupawong</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2012</year>;<volume>206</volume>(<issue>3</issue>):<fpage>389</fpage>&#x02013;<lpage>98</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jis357</pub-id>
<!--<pub-id pub-id-type="pmcid">3490697</pub-id>-->
<?supplied-pmid 22615312?><pub-id pub-id-type="pmid">22615312</pub-id></mixed-citation></ref><ref id="ref-23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KB</given-names></name><name><surname>Chunsuttiwat</surname><given-names>S</given-names></name><name><surname>Nisalak</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study.</article-title>
<source><italic toggle="yes">Lancet.</italic></source>
<year>2007</year>;<volume>369</volume>(<issue>9571</issue>):<fpage>1452</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60671-0</pub-id>
<?supplied-pmid 17467515?><pub-id pub-id-type="pmid">17467515</pub-id></mixed-citation></ref><ref id="ref-24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buchy</surname><given-names>P</given-names></name><name><surname>Vo</surname><given-names>VL</given-names></name><name><surname>Bui</surname><given-names>KT</given-names></name><etal/></person-group>:
<article-title>Secondary dengue virus type 4 infections in Vietnam.</article-title>
<source><italic toggle="yes">Southeast Asian J Trop Med Public Health.</italic></source>
<year>2005</year>;<volume>36</volume>(<issue>1</issue>):<fpage>178</fpage>&#x02013;<lpage>85</lpage>.
<?supplied-pmid 15906664?><pub-id pub-id-type="pmid">15906664</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/14184">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thai</surname><given-names>KT</given-names></name><name><surname>Phuong</surname><given-names>HL</given-names></name><name><surname>Thanh Nga</surname><given-names>TT</given-names></name><etal/></person-group>:
<article-title>Clinical, epidemiological and virological features of Dengue virus infections in Vietnamese patients presenting to primary care facilities with acute undifferentiated fever.</article-title>
<source><italic toggle="yes">J Infect.</italic></source>
<year>2010</year>;<volume>60</volume>(<issue>3</issue>):<fpage>229</fpage>&#x02013;<lpage>37</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jinf.2010.01.003</pub-id>
<!--<pub-id pub-id-type="pmcid">2954363</pub-id>-->
<?supplied-pmid 20080126?><pub-id pub-id-type="pmid">20080126</pub-id></mixed-citation></ref><ref id="ref-26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>DW</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Kalayanarooj</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2000</year>;<volume>181</volume>(<issue>1</issue>):<fpage>2</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1086/315215</pub-id>
<?supplied-pmid 10608744?><pub-id pub-id-type="pmid">10608744</pub-id></mixed-citation></ref><ref id="ref-27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Kuan</surname><given-names>G</given-names></name><name><surname>Mercado</surname><given-names>JC</given-names></name><etal/></person-group>:
<article-title>The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2013</year>;<volume>7</volume>(<issue>9</issue>):<fpage>e2462</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0002462</pub-id>
<!--<pub-id pub-id-type="pmcid">3784501</pub-id>-->
<?supplied-pmid 24086788?><pub-id pub-id-type="pmid">24086788</pub-id></mixed-citation></ref><ref id="ref-28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group>:
<article-title>Neutralization and antibody-dependent enhancement of dengue viruses.</article-title>
<source><italic toggle="yes">Adv Virus Res.</italic></source>
<year>2003</year>;<volume>60</volume>:<fpage>421</fpage>&#x02013;<lpage>67</lpage>.
<pub-id pub-id-type="doi">10.1016/S0065-3527(03)60011-4</pub-id>
<?supplied-pmid 14689700?><pub-id pub-id-type="pmid">14689700</pub-id></mixed-citation></ref><ref id="ref-29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sangkawibha</surname><given-names>N</given-names></name><name><surname>Rojanasuphot</surname><given-names>S</given-names></name><name><surname>Ahandrik</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.</article-title>
<source><italic toggle="yes">Am J Epidemiol.</italic></source>
<year>1984</year>;<volume>120</volume>(<issue>5</issue>):<fpage>653</fpage>&#x02013;<lpage>69</lpage>.
<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a113932</pub-id>
<?supplied-pmid 6496446?><pub-id pub-id-type="pmid">6496446</pub-id></mixed-citation></ref><ref id="ref-30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guzman</surname><given-names>MG</given-names></name><name><surname>Kouri</surname><given-names>G</given-names></name><name><surname>Valdes</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Enhanced severity of secondary dengue 2 infections occurring at an interval of 20 compared with 4 years after dengue 1 infection.</article-title>
<source><italic toggle="yes">PAHO J Epidemol.</italic></source>
<year>2002</year>;<volume>81</volume>:<fpage>223</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="ref-31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guzman</surname><given-names>MG</given-names></name><name><surname>Alvarez</surname><given-names>A</given-names></name><name><surname>Vazquez</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001&#x02013;2002.</article-title>
<source><italic toggle="yes">Int J Infect Dis.</italic></source>
<year>2012</year>;<volume>16</volume>(<issue>3</issue>):<fpage>e198</fpage>&#x02013;<lpage>e203</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ijid.2011.09.026</pub-id>
<?supplied-pmid 22277259?><pub-id pub-id-type="pmid">22277259</pub-id></mixed-citation></ref><ref id="ref-32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hubert</surname><given-names>B</given-names></name><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group>:
<article-title>Dengue 1 virus and dengue hemorrhagic fever, French Polynesia, 2001.</article-title>
<source><italic toggle="yes">Emerg Infect Dis.</italic></source>
<year>2009</year>;<volume>15</volume>(<issue>8</issue>):<fpage>1265</fpage>&#x02013;<lpage>70</lpage>.
<pub-id pub-id-type="doi">10.3201/eid1508.081500</pub-id>
<?supplied-pmid 19751589?><pub-id pub-id-type="pmid">19751589</pub-id></mixed-citation></ref><ref id="ref-33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gamble</surname><given-names>J</given-names></name><name><surname>Bethell</surname><given-names>D</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><etal/></person-group>:
<article-title>Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock?</article-title>
<source><italic toggle="yes">Clin Sci (Lond).</italic></source>
<year>2000</year>;<volume>98</volume>(<issue>2</issue>):<fpage>211</fpage>&#x02013;<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1042/cs0980211</pub-id>
<?supplied-pmid 10657278?><pub-id pub-id-type="pmid">10657278</pub-id></mixed-citation></ref><ref id="ref-34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KB</given-names></name><name><surname>Gibbons</surname><given-names>RV</given-names></name><name><surname>Cummings</surname><given-names>DA</given-names></name><etal/></person-group>:
<article-title>A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2014</year>;<volume>209</volume>(<issue>3</issue>):<fpage>360</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jit436</pub-id>
<!--<pub-id pub-id-type="pmcid">3883164</pub-id>-->
<?supplied-pmid 23964110?><pub-id pub-id-type="pmid">23964110</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718078559">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katzelnick</surname><given-names>LC</given-names></name><name><surname>Gresh</surname><given-names>L</given-names></name><name><surname>Halloran</surname><given-names>ME</given-names></name><etal/></person-group>:
<article-title>Antibody-dependent enhancement of severe dengue disease in humans.</article-title>
<source><italic toggle="yes">Science.</italic></source>
<year>2017</year>;<volume>358</volume>(<issue>6365</issue>):<fpage>929</fpage>&#x02013;<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1126/science.aan6836</pub-id>
<!--<pub-id pub-id-type="pmcid">5858873</pub-id>-->
<?supplied-pmid 29097492?><pub-id pub-id-type="pmid">29097492</pub-id></mixed-citation></ref><ref id="ref-36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salje</surname><given-names>H</given-names></name><name><surname>Cummings</surname><given-names>DAT</given-names></name><name><surname>Rodriguez-Barraquer</surname><given-names>I</given-names></name><etal/></person-group>:
<article-title>Reconstruction of antibody dynamics and infection histories to evaluate dengue risk.</article-title>
<source><italic toggle="yes">Nature.</italic></source>
<year>2018</year>;<volume>557</volume>(<issue>7707</issue>):<fpage>719</fpage>&#x02013;<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1038/s41586-018-0157-4</pub-id>
<!--<pub-id pub-id-type="pmcid">6064976</pub-id>-->
<?supplied-pmid 29795354?><pub-id pub-id-type="pmid">29795354</pub-id></mixed-citation></ref><ref id="ref-37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guzman</surname><given-names>MG</given-names></name><name><surname>Alvarez</surname><given-names>M</given-names></name><name><surname>Rodriguez-Roche</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>Neutralizing antibodies after infection with dengue 1 virus.</article-title>
<source><italic toggle="yes">Emerg Infect Dis.</italic></source>
<year>2007</year>;<volume>13</volume>(<issue>2</issue>):<fpage>282</fpage>&#x02013;<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.3201/eid1302.060539</pub-id>
<!--<pub-id pub-id-type="pmcid">2725871</pub-id>-->
<?supplied-pmid 17479892?><pub-id pub-id-type="pmid">17479892</pub-id></mixed-citation></ref><ref id="ref-38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lau</surname><given-names>L</given-names></name><name><surname>Green</surname><given-names>AM</given-names></name><name><surname>Balmaseda</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.</article-title>
<source><italic toggle="yes">J Clin Virol.</italic></source>
<year>2015</year>;<volume>69</volume>:<fpage>63</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jcv.2015.06.003</pub-id>
<!--<pub-id pub-id-type="pmcid">4978614</pub-id>-->
<?supplied-pmid 26209381?><pub-id pub-id-type="pmid">26209381</pub-id></mixed-citation></ref><ref id="ref-39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trung</surname><given-names>DT</given-names></name><name><surname>Thao le</surname><given-names>TT</given-names></name><name><surname>Dung</surname><given-names>NM</given-names></name><etal/></person-group>:
<article-title>Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2012</year>;<volume>6</volume>(<issue>6</issue>):<fpage>e1679</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0001679</pub-id>
<!--<pub-id pub-id-type="pmcid">3383761</pub-id>-->
<?supplied-pmid 22745839?><pub-id pub-id-type="pmid">22745839</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/720295157">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xavier-Carvalho</surname><given-names>C</given-names></name><name><surname>Cardoso</surname><given-names>CC</given-names></name><name><surname>de Souza Kehdy</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>Host genetics and dengue fever.</article-title>
<source><italic toggle="yes">Infect Genet Evol.</italic></source>
<year>2017</year>;<volume>56</volume>:<fpage>99</fpage>&#x02013;<lpage>110</lpage>.
<pub-id pub-id-type="doi">10.1016/j.meegid.2017.11.009</pub-id>
<?supplied-pmid 29133029?><pub-id pub-id-type="pmid">29133029</pub-id></mixed-citation></ref><ref id="ref-41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boonnak</surname><given-names>K</given-names></name><name><surname>Dambach</surname><given-names>KM</given-names></name><name><surname>Donofrio</surname><given-names>GC</given-names></name><etal/></person-group>:
<article-title>Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2011</year>;<volume>85</volume>(<issue>4</issue>):<fpage>1671</fpage>&#x02013;<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.00220-10</pub-id>
<!--<pub-id pub-id-type="pmcid">3028884</pub-id>-->
<?supplied-pmid 21123382?><pub-id pub-id-type="pmid">21123382</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/9261959">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lert-Itthiporn</surname><given-names>W</given-names></name><name><surname>Suktitipat</surname><given-names>B</given-names></name><name><surname>Grove</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>Validation of genotype imputation in Southeast Asian populations and the effect of single nucleotide polymorphism annotation on imputation outcome.</article-title>
<source><italic toggle="yes">BMC Med Genet.</italic></source>
<year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>23</fpage>.
<pub-id pub-id-type="doi">10.1186/s12881-018-0534-8</pub-id>
<!--<pub-id pub-id-type="pmcid">5812212</pub-id>-->
<?supplied-pmid 29439659?><pub-id pub-id-type="pmid">29439659</pub-id></mixed-citation></ref><ref id="ref-43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>M</given-names></name><name><surname>Lert-Itthiporn</surname><given-names>W</given-names></name><name><surname>Cavadas</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2018</year>;<volume>12</volume>(<issue>2</issue>):<fpage>e0006202</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0006202</pub-id>
<!--<pub-id pub-id-type="pmcid">5813895</pub-id>-->
<?supplied-pmid 29447178?><pub-id pub-id-type="pmid">29447178</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732674902">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sierra</surname><given-names>B</given-names></name><name><surname>Triska</surname><given-names>P</given-names></name><name><surname>Soares</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>
<italic>OSBPL10, RXRA</italic> and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans.</article-title>
<source><italic toggle="yes">PLoS Pathog.</italic></source>
<year>2017</year>;<volume>13</volume>(<issue>2</issue>):<fpage>e1006220</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.ppat.1006220</pub-id>
<!--<pub-id pub-id-type="pmcid">5344536</pub-id>-->
<?supplied-pmid 28241052?><pub-id pub-id-type="pmid">28241052</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727348753">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-45"><label>45</label><mixed-citation publication-type="book">
<collab>WHO</collab>:
<article-title>Dengue: Guidelines for diagnosis, treatment prevention and control</article-title>. Geneva: WHO; 2009;
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names>KD</given-names></name><name><surname>Lum</surname><given-names>L</given-names></name><name><surname>Alexander</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Vascular leakage in dengue--clinical spectrum and influence of parenteral fluid therapy.</article-title>
<source><italic toggle="yes">Trop Med Int Health.</italic></source>
<year>2016</year>;<volume>21</volume>(<issue>3</issue>):<fpage>445</fpage>&#x02013;<lpage>53</lpage>.
<pub-id pub-id-type="doi">10.1111/tmi.12666</pub-id>
<?supplied-pmid 26752720?><pub-id pub-id-type="pmid">26752720</pub-id></mixed-citation></ref><ref id="ref-47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ellis</surname><given-names>EM</given-names></name><name><surname>Sharp</surname><given-names>TM</given-names></name><name><surname>P&#x000e9;rez-Padilla</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic Lymphohistiocytosis in Puerto Rico, 2008 - 2013.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2016</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e0004939</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0004939</pub-id>
<!--<pub-id pub-id-type="pmcid">4996422</pub-id>-->
<?supplied-pmid 27556807?><pub-id pub-id-type="pmid">27556807</pub-id></mixed-citation></ref><ref id="ref-48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giang</surname><given-names>HTN</given-names></name><name><surname>Banno</surname><given-names>K</given-names></name><name><surname>Minh</surname><given-names>LHN</given-names></name><etal/></person-group>:
<article-title>Dengue hemophagocytic syndrome: A systematic review and meta-analysis on epidemiology, clinical signs, outcomes, and risk factors.</article-title>
<source><italic toggle="yes">Rev Med Virol.</italic></source>
<year>2018</year>;<volume>28</volume>(<issue>6</issue>):<fpage>e2005</fpage>.
<pub-id pub-id-type="doi">10.1002/rmv.2005</pub-id>
<?supplied-pmid 30109914?><pub-id pub-id-type="pmid">30109914</pub-id></mixed-citation></ref><ref id="ref-49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan Jamaludin</surname><given-names>WF</given-names></name><name><surname>Periyasamy</surname><given-names>P</given-names></name><name><surname>Wan Mat</surname><given-names>WR</given-names></name><etal/></person-group>:
<article-title>Dengue infection associated hemophagocytic syndrome: Therapeutic interventions and outcome.</article-title>
<source><italic toggle="yes">J Clin Virol.</italic></source>
<year>2015</year>;<volume>69</volume>:<fpage>91</fpage>&#x02013;<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jcv.2015.06.004</pub-id>
<?supplied-pmid 26209387?><pub-id pub-id-type="pmid">26209387</pub-id></mixed-citation></ref><ref id="ref-50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Vu</surname><given-names>TT</given-names></name><etal/></person-group>:
<article-title>Corticosteroids for dengue - why don't they work?</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2013</year>;<volume>7</volume>(<issue>12</issue>):<fpage>e2592</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0002592</pub-id>
<!--<pub-id pub-id-type="pmcid">3861232</pub-id>-->
<?supplied-pmid 24349598?><pub-id pub-id-type="pmid">24349598</pub-id></mixed-citation></ref><ref id="ref-51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lum</surname><given-names>LC</given-names></name><name><surname>Abdel-Latif</surname><given-names>Mel-A</given-names></name><name><surname>Goh</surname><given-names>AY</given-names></name><etal/></person-group>:
<article-title>Preventive transfusion in Dengue shock syndrome-is it necessary?</article-title>
<source><italic toggle="yes">J Pediatr.</italic></source>
<year>2003</year>;<volume>143</volume>(<issue>5</issue>):<fpage>682</fpage>&#x02013;<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1067/S0022-3476(03)00503-1</pub-id>
<?supplied-pmid 14615749?><pub-id pub-id-type="pmid">14615749</pub-id></mixed-citation></ref><ref id="ref-52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitehorn</surname><given-names>J</given-names></name><name><surname>Rodriguez Roche</surname><given-names>R</given-names></name><name><surname>Guzman</surname><given-names>MG</given-names></name><etal/></person-group>:
<article-title>Prophylactic platelets in dengue: survey responses highlight lack of an evidence base.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2012</year>;<volume>6</volume>(<issue>6</issue>):<fpage>e1716</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0001716</pub-id>
<!--<pub-id pub-id-type="pmcid">3383756</pub-id>-->
<?supplied-pmid 22745847?><pub-id pub-id-type="pmid">22745847</pub-id></mixed-citation></ref><ref id="ref-53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan Assir</surname><given-names>MZ</given-names></name><name><surname>Ahmad</surname><given-names>F</given-names></name></person-group>:
<article-title>Prophylactic platelet transfusion does not reduce risk of clinical bleeding in adults with dengue and thrombocytopaenia.</article-title>
<source><italic toggle="yes">Evid Based Med.</italic></source>
<year>2017</year>;<volume>22</volume>(<issue>6</issue>):<fpage>225</fpage>.
<pub-id pub-id-type="doi">10.1136/ebmed-2017-110745</pub-id>
<?supplied-pmid 29097447?><pub-id pub-id-type="pmid">29097447</pub-id></mixed-citation></ref><ref id="ref-54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rajapakse</surname><given-names>S</given-names></name><name><surname>de Silva</surname><given-names>NL</given-names></name><name><surname>Weeratunga</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review.</article-title>
<source><italic toggle="yes">Trans R Soc Trop Med Hyg.</italic></source>
<year>2017</year>;<volume>111</volume>(<issue>10</issue>):<fpage>433</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1093/trstmh/trx079</pub-id>
<?supplied-pmid 29385613?><pub-id pub-id-type="pmid">29385613</pub-id></mixed-citation></ref><ref id="ref-55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>Archuleta</surname><given-names>S</given-names></name><name><surname>Syed-Omar</surname><given-names>SF</given-names></name><etal/></person-group>:
<article-title>Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial.</article-title>
<source><italic toggle="yes">Lancet.</italic></source>
<year>2017</year>;<volume>389</volume>(<issue>10079</issue>):<fpage>1611</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(17)30269-6</pub-id>
<?supplied-pmid 28283286?><pub-id pub-id-type="pmid">28283286</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727390450">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yacoub</surname><given-names>S</given-names></name><name><surname>Trung</surname><given-names>TH</given-names></name><name><surname>Lam</surname><given-names>PK</given-names></name><etal/></person-group>:
<article-title>Cardio-haemodynamic assessment and venous lactate in severe dengue: Relationship with recurrent shock and respiratory distress.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2017</year>;<volume>11</volume>(<issue>7</issue>):<fpage>e0005740</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0005740</pub-id>
<!--<pub-id pub-id-type="pmcid">5519203</pub-id>-->
<?supplied-pmid 28692675?><pub-id pub-id-type="pmid">28692675</pub-id></mixed-citation></ref><ref id="ref-57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>PK</given-names></name><name><surname>Ngoc</surname><given-names>TV</given-names></name><name><surname>Thu Thuy</surname><given-names>TT</given-names></name><etal/></person-group>:
<article-title>The value of daily platelet counts for predicting dengue shock syndrome: Results from a prospective observational study of 2301 Vietnamese children with dengue.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2017</year>;<volume>11</volume>(<issue>4</issue>):<fpage>e0005498</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0005498</pub-id>
<!--<pub-id pub-id-type="pmcid">5407568</pub-id>-->
<?supplied-pmid 28448490?><pub-id pub-id-type="pmid">28448490</pub-id></mixed-citation></ref><ref id="ref-58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stoddard</surname><given-names>ST</given-names></name><name><surname>Morrison</surname><given-names>AC</given-names></name><name><surname>Vazquez-Prokopec</surname><given-names>GM</given-names></name><etal/></person-group>:
<article-title>The role of human movement in the transmission of vector-borne pathogens.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2009</year>;<volume>3</volume>(<issue>7</issue>):<fpage>e481</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0000481</pub-id>
<!--<pub-id pub-id-type="pmcid">2710008</pub-id>-->
<?supplied-pmid 19621090?><pub-id pub-id-type="pmid">19621090</pub-id></mixed-citation></ref><ref id="ref-59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stoddard</surname><given-names>ST</given-names></name><name><surname>Forshey</surname><given-names>BM</given-names></name><name><surname>Morrison</surname><given-names>AC</given-names></name><etal/></person-group>:
<article-title>House-to-house human movement drives dengue virus transmission.</article-title>
<source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source>
<year>2013</year>;<volume>110</volume>(<issue>3</issue>):<fpage>994</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1213349110</pub-id>
<!--<pub-id pub-id-type="pmcid">3549073</pub-id>-->
<?supplied-pmid 23277539?><pub-id pub-id-type="pmid">23277539</pub-id></mixed-citation></ref><ref id="ref-60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perkins</surname><given-names>TA</given-names></name><name><surname>Paz-Soldan</surname><given-names>VA</given-names></name><name><surname>Stoddard</surname><given-names>ST</given-names></name><etal/></person-group>:
<article-title>Calling in sick: impacts of fever on intra-urban human mobility.</article-title>
<source><italic toggle="yes">Proc Biol Sci.</italic></source>
<year>2016</year>;<volume>283</volume>(<issue>1834</issue>): pii: 20160390.
<pub-id pub-id-type="doi">10.1098/rspb.2016.0390</pub-id>
<!--<pub-id pub-id-type="pmcid">4947886</pub-id>-->
<?supplied-pmid 27412286?><pub-id pub-id-type="pmid">27412286</pub-id></mixed-citation></ref><ref id="ref-61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quyen</surname><given-names>DL</given-names></name><name><surname>Thanh Le</surname><given-names>N</given-names></name><name><surname>Van Anh</surname><given-names>CT</given-names></name><etal/></person-group>:
<article-title>Epidemiological, Serological, and Virological Features of Dengue in Nha Trang City, Vietnam.</article-title>
<source><italic toggle="yes">Am J Trop Med Hyg.</italic></source>
<year>2018</year>;<volume>98</volume>(<issue>2</issue>):<fpage>402</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.17-0630</pub-id>
<!--<pub-id pub-id-type="pmcid">5929208</pub-id>-->
<?supplied-pmid 29313471?><pub-id pub-id-type="pmid">29313471</pub-id></mixed-citation></ref><ref id="ref-62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Indriani</surname><given-names>C</given-names></name><name><surname>Ahmad</surname><given-names>RA</given-names></name><name><surname>Wiratama</surname><given-names>BS</given-names></name><etal/></person-group>:
<article-title>Baseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a Randomized Controlled Trial of
<italic>Wolbachia</italic> for Arboviral Disease Control.</article-title>
<source><italic toggle="yes">Am J Trop Med Hyg.</italic></source>
<year>2018</year>;<volume>99</volume>(<issue>5</issue>):<fpage>1299</fpage>&#x02013;<lpage>307</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.18-0315</pub-id>
<!--<pub-id pub-id-type="pmcid">6221224</pub-id>-->
<?supplied-pmid 30226138?><pub-id pub-id-type="pmid">30226138</pub-id></mixed-citation></ref><ref id="ref-63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ten Bosch</surname><given-names>QA</given-names></name><name><surname>Clapham</surname><given-names>HE</given-names></name><name><surname>Lambrechts</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Contributions from the silent majority dominate dengue virus transmission.</article-title>
<source><italic toggle="yes">PLoS Pathog.</italic></source>
<year>2018</year>;<volume>14</volume>(<issue>5</issue>):<fpage>e1006965</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.ppat.1006965</pub-id>
<!--<pub-id pub-id-type="pmcid">5933708</pub-id>-->
<?supplied-pmid 29723307?><pub-id pub-id-type="pmid">29723307</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/733160338">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duong</surname><given-names>V</given-names></name><name><surname>Lambrechts</surname><given-names>L</given-names></name><name><surname>Paul</surname><given-names>RE</given-names></name><etal/></person-group>:
<article-title>Asymptomatic humans transmit dengue virus to mosquitoes.</article-title>
<source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source>
<year>2015</year>;<volume>112</volume>(<issue>47</issue>):<fpage>14688</fpage>&#x02013;<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1508114112</pub-id>
<!--<pub-id pub-id-type="pmcid">4664300</pub-id>-->
<?supplied-pmid 26553981?><pub-id pub-id-type="pmid">26553981</pub-id></mixed-citation></ref><ref id="ref-65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Espa&#x000f1;a</surname><given-names>G</given-names></name><name><surname>Hogea</surname><given-names>C</given-names></name><name><surname>Guignard</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms.</article-title>
<source><italic toggle="yes">PLoS One.</italic></source>
<year>2019</year>;<volume>14</volume>(<issue>1</issue>):<fpage>e0210041</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0210041</pub-id>
<!--<pub-id pub-id-type="pmcid">6347271</pub-id>-->
<?supplied-pmid 30682037?><pub-id pub-id-type="pmid">30682037</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734924980">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>GS</given-names></name><name><surname>Kikuti</surname><given-names>M</given-names></name><name><surname>Tauro</surname><given-names>LB</given-names></name><etal/></person-group>:
<article-title>Does immunity after Zika virus infection cross-protect against dengue?</article-title>
<source><italic toggle="yes">Lancet Glob Health.</italic></source>
<year>2018</year>;<volume>6</volume>(<issue>2</issue>):<fpage>e140</fpage>&#x02013;<lpage>e141</lpage>.
<pub-id pub-id-type="doi">10.1016/S2214-109X(17)30496-5</pub-id>
<?supplied-pmid 29389533?><pub-id pub-id-type="pmid">29389533</pub-id></mixed-citation></ref><ref id="ref-67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perez</surname><given-names>F</given-names></name><name><surname>Llau</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>G</given-names></name><etal/></person-group>:
<article-title>The decline of dengue in the Americas in 2017: discussion of multiple hypotheses.</article-title>
<source><italic toggle="yes">Trop Med Int Health.</italic></source>
<year>2019</year>;<volume>24</volume>(<issue>4</issue>):<fpage>442</fpage>&#x02013;<lpage>53</lpage>.
<pub-id pub-id-type="doi">10.1111/tmi.13200</pub-id>
<?supplied-pmid 30624838?><pub-id pub-id-type="pmid">30624838</pub-id></mixed-citation></ref><ref id="ref-68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>GS</given-names></name><name><surname>Kikuti</surname><given-names>M</given-names></name><name><surname>Tauro</surname><given-names>LB</given-names></name><etal/></person-group>:
<article-title>Can Zika virus antibodies cross-protect against dengue virus? - Authors' reply.</article-title>
<source><italic toggle="yes">Lancet Glob Health.</italic></source>
<year>2018</year>;<volume>6</volume>(<issue>5</issue>):<fpage>e495</fpage>.
<pub-id pub-id-type="doi">10.1016/S2214-109X(18)30123-2</pub-id>
<?supplied-pmid 29653620?><pub-id pub-id-type="pmid">29653620</pub-id></mixed-citation></ref><ref id="ref-69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group>:
<article-title>Mosquito-borne haemorrhagic fevers of South and South-East Asia.</article-title>
<source><italic toggle="yes">Bull World Health Organ.</italic></source>
<year>1966</year>;<volume>35</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>15</lpage>.
<!--<pub-id pub-id-type="pmcid">2476178</pub-id>-->
<?supplied-pmid 5297536?><pub-id pub-id-type="pmid">5297536</pub-id></mixed-citation></ref><ref id="ref-70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salje</surname><given-names>H</given-names></name><name><surname>Paul</surname><given-names>KK</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>Nationally-representative serostudy of dengue in Bangladesh allows generalizable disease burden estimates.</article-title>
<source><italic toggle="yes">eLife.</italic></source>
<year>2019</year>;<volume>8</volume>: pii: e42869.
<pub-id pub-id-type="doi">10.7554/eLife.42869</pub-id>
<!--<pub-id pub-id-type="pmcid">6513551</pub-id>-->
<?supplied-pmid 30958263?><pub-id pub-id-type="pmid">30958263</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/735536705">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Vasconcelos</surname><given-names>PF</given-names></name></person-group>:
<article-title>Yellow fever.</article-title>
<source><italic toggle="yes">J Clin Virol.</italic></source>
<year>2015</year>;<volume>64</volume>:<fpage>160</fpage>&#x02013;<lpage>73</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jcv.2014.08.030</pub-id>
<?supplied-pmid 25453327?><pub-id pub-id-type="pmid">25453327</pub-id></mixed-citation></ref><ref id="ref-72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turell</surname><given-names>MJ</given-names></name><name><surname>Gozalo</surname><given-names>AS</given-names></name><name><surname>Guevara</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Lack of Evidence of Sylvatic Transmission of Dengue Viruses in the Amazon Rainforest Near Iquitos, Peru.</article-title>
<source><italic toggle="yes">Vector Borne Zoonotic Dis.</italic></source>
<year>2019</year>.
<pub-id pub-id-type="doi">10.1089/vbz.2018.2408</pub-id>
<?supplied-pmid 30964397?><pub-id pub-id-type="pmid">30964397</pub-id></mixed-citation></ref><ref id="ref-73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name><name><surname>Nimmannitya</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>SN</given-names></name></person-group>:
<article-title>Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered.</article-title>
<source><italic toggle="yes">Yale J Biol Med.</italic></source>
<year>1970</year>;<volume>42</volume>(<issue>5</issue>):<fpage>311</fpage>&#x02013;<lpage>28</lpage>.
<!--<pub-id pub-id-type="pmcid">2591704</pub-id>-->
<?supplied-pmid 5419206?><pub-id pub-id-type="pmid">5419206</pub-id></mixed-citation></ref><ref id="ref-74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aye</surname><given-names>KS</given-names></name><name><surname>Charngkaew</surname><given-names>K</given-names></name><name><surname>Win</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar.</article-title>
<source><italic toggle="yes">Hum Pathol.</italic></source>
<year>2014</year>;<volume>45</volume>(<issue>6</issue>):<fpage>1221</fpage>&#x02013;<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1016/j.humpath.2014.01.022</pub-id>
<?supplied-pmid 24767772?><pub-id pub-id-type="pmid">24767772</pub-id></mixed-citation></ref><ref id="ref-75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group>:
<article-title>Pathogenesis of dengue: challenges to molecular biology.</article-title>
<source><italic toggle="yes">Science.</italic></source>
<year>1988</year>;<volume>239</volume>(<issue>4839</issue>):<fpage>476</fpage>&#x02013;<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.1126/science.3277268</pub-id>
<?supplied-pmid 3277268?><pub-id pub-id-type="pmid">3277268</pub-id></mixed-citation></ref><ref id="ref-76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Libraty</surname><given-names>DH</given-names></name><name><surname>Endy</surname><given-names>TP</given-names></name><name><surname>Houng</surname><given-names>HS</given-names></name><etal/></person-group>:
<article-title>Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2002</year>;<volume>185</volume>(<issue>9</issue>):<fpage>1213</fpage>&#x02013;<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1086/340365</pub-id>
<?supplied-pmid 12001037?><pub-id pub-id-type="pmid">12001037</pub-id></mixed-citation></ref><ref id="ref-77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>PK</given-names></name><name><surname>Tam</surname><given-names>DT</given-names></name><name><surname>Diet</surname><given-names>TV</given-names></name><etal/></person-group>:
<article-title>Clinical characteristics of Dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital.</article-title>
<source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2013</year>;<volume>57</volume>(<issue>11</issue>):<fpage>1577</fpage>&#x02013;<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1093/cid/cit594</pub-id>
<!--<pub-id pub-id-type="pmcid">3814826</pub-id>-->
<?supplied-pmid 24046311?><pub-id pub-id-type="pmid">24046311</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718114088">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name><name><surname>Mahalingam</surname><given-names>S</given-names></name><name><surname>Marovich</surname><given-names>MA</given-names></name><etal/></person-group>:
<article-title>Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.</article-title>
<source><italic toggle="yes">Lancet Infect Dis.</italic></source>
<year>2010</year>;<volume>10</volume>(<issue>10</issue>):<fpage>712</fpage>&#x02013;<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1016/S1473-3099(10)70166-3</pub-id>
<!--<pub-id pub-id-type="pmcid">3057165</pub-id>-->
<?supplied-pmid 20883967?><pub-id pub-id-type="pmid">20883967</pub-id></mixed-citation></ref><ref id="ref-79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name><name><surname>Shotwell</surname><given-names>H</given-names></name><name><surname>Casals</surname><given-names>J</given-names></name></person-group>:
<article-title>Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>1973</year>;<volume>128</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/128.1.15</pub-id>
<?supplied-pmid 4198024?><pub-id pub-id-type="pmid">4198024</pub-id></mixed-citation></ref><ref id="ref-80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talarico</surname><given-names>LB</given-names></name><name><surname>Batalle</surname><given-names>JP</given-names></name><name><surname>Byrne</surname><given-names>AB</given-names></name><etal/></person-group>:
<article-title>The Role of Heterotypic DENV-specific CD8
<sup>+</sup>T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection.</article-title>
<source><italic toggle="yes">EBioMedicine.</italic></source>
<year>2017</year>;<volume>20</volume>:<fpage>202</fpage>&#x02013;<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ebiom.2017.04.033</pub-id>
<!--<pub-id pub-id-type="pmcid">5478214</pub-id>-->
<?supplied-pmid 28483582?><pub-id pub-id-type="pmid">28483582</pub-id></mixed-citation></ref><ref id="ref-81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zellweger</surname><given-names>RM</given-names></name><name><surname>Shresta</surname><given-names>S</given-names></name></person-group>:
<article-title>Mouse models to study dengue virus immunology and pathogenesis.</article-title>
<source><italic toggle="yes">Front Immunol.</italic></source>
<year>2014</year>;<volume>5</volume>:<fpage>151</fpage>.
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00151</pub-id>
<!--<pub-id pub-id-type="pmcid">3989707</pub-id>-->
<?supplied-pmid 24782859?><pub-id pub-id-type="pmid">24782859</pub-id></mixed-citation></ref><ref id="ref-82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ng</surname><given-names>JK</given-names></name><name><surname>Zhang</surname><given-names>SL</given-names></name><name><surname>Tan</surname><given-names>HC</given-names></name><etal/></person-group>:
<article-title>First experimental
<italic>in vivo</italic> model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies.</article-title>
<source><italic toggle="yes">PLoS Pathog.</italic></source>
<year>2014</year>;<volume>10</volume>(<issue>4</issue>):<fpage>e1004031</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.ppat.1004031</pub-id>
<!--<pub-id pub-id-type="pmcid">3974839</pub-id>-->
<?supplied-pmid 24699622?><pub-id pub-id-type="pmid">24699622</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718338167">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>XN</given-names></name><etal/></person-group>:
<article-title>Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.</article-title>
<source><italic toggle="yes">Nat Med.</italic></source>
<year>2003</year>;<volume>9</volume>(<issue>7</issue>):<fpage>921</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/nm887</pub-id>
<?supplied-pmid 12808447?><pub-id pub-id-type="pmid">12808447</pub-id></mixed-citation></ref><ref id="ref-84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srikiatkhachorn</surname><given-names>A</given-names></name><name><surname>Mathew</surname><given-names>A</given-names></name><name><surname>Rothman</surname><given-names>AL</given-names></name></person-group>:
<article-title>Immune-mediated cytokine storm and its role in severe dengue.</article-title>
<source><italic toggle="yes">Semin Immunopathol.</italic></source>
<year>2017</year>;<volume>39</volume>(<issue>5</issue>):<fpage>563</fpage>&#x02013;<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1007/s00281-017-0625-1</pub-id>
<!--<pub-id pub-id-type="pmcid">5496927</pub-id>-->
<?supplied-pmid 28401256?><pub-id pub-id-type="pmid">28401256</pub-id></mixed-citation></ref><ref id="ref-85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>CF</given-names></name><name><surname>Lei</surname><given-names>HY</given-names></name><name><surname>Shiau</surname><given-names>Al</given-names></name><etal/></person-group>:
<article-title>Antibodies from dengue patient sera cross-react with endothelial cells and induce damage.</article-title>
<source><italic toggle="yes">J Med Virol.</italic></source>
<year>2003</year>;<volume>69</volume>(<issue>1</issue>):<fpage>82</fpage>&#x02013;<lpage>90</lpage>.
<pub-id pub-id-type="doi">10.1002/jmv.10261</pub-id>
<?supplied-pmid 12436482?><pub-id pub-id-type="pmid">12436482</pub-id></mixed-citation></ref><ref id="ref-86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>SW</given-names></name><name><surname>Wu-Hsieh</surname><given-names>BA</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><etal/></person-group>:
<article-title>The monocyte-macrophage-mast cell axis in dengue pathogenesis.</article-title>
<source><italic toggle="yes">J Biomed Sci.</italic></source>
<year>2018</year>;<volume>25</volume>(<issue>1</issue>):<fpage>77</fpage>.
<pub-id pub-id-type="doi">10.1186/s12929-018-0482-9</pub-id>
<!--<pub-id pub-id-type="pmcid">6225659</pub-id>-->
<?supplied-pmid 30409217?><pub-id pub-id-type="pmid">30409217</pub-id></mixed-citation></ref><ref id="ref-87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schlesinger</surname><given-names>JJ</given-names></name><name><surname>Brandriss</surname><given-names>MW</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name></person-group>:
<article-title>Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1.</article-title>
<source><italic toggle="yes">J Gen Virol.</italic></source>
<year>1987</year>;<volume>68</volume>(<issue>Pt 3</issue>):<fpage>853</fpage>&#x02013;<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1099/0022-1317-68-3-853</pub-id>
<?supplied-pmid 3819700?><pub-id pub-id-type="pmid">3819700</pub-id></mixed-citation></ref><ref id="ref-88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Puerta-Guardo</surname><given-names>H</given-names></name><name><surname>Glasner</surname><given-names>DR</given-names></name><name><surname>Espinosa</surname><given-names>DA</given-names></name><etal/></person-group>:
<article-title>Flavivirus NS1 Triggers Tissue-Specific Vascular Endothelial Dysfunction Reflecting Disease Tropism.</article-title>
<source><italic toggle="yes">Cell Rep.</italic></source>
<year>2019</year>;<volume>26</volume>(<issue>6</issue>):<fpage>1598</fpage>&#x02013;<lpage>1613.e8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.celrep.2019.01.036</pub-id>
<?supplied-pmid 30726741?><pub-id pub-id-type="pmid">30726741</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/735022290">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Young</surname><given-names>PR</given-names></name><name><surname>Hilditch</surname><given-names>PA</given-names></name><name><surname>Bletchly</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients.</article-title>
<source><italic toggle="yes">J Clin Microbiol.</italic></source>
<year>2000</year>;<volume>38</volume>(<issue>3</issue>):<fpage>1053</fpage>&#x02013;<lpage>7</lpage>.
<!--<pub-id pub-id-type="pmcid">86336</pub-id>-->
<?supplied-pmid 10698995?><pub-id pub-id-type="pmid">10698995</pub-id></mixed-citation></ref><ref id="ref-90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Avirutnan</surname><given-names>P</given-names></name><name><surname>Punyadee</surname><given-names>N</given-names></name><name><surname>Noisakran</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2006</year>;<volume>193</volume>(<issue>8</issue>):<fpage>1078</fpage>&#x02013;<lpage>88</lpage>.
<pub-id pub-id-type="doi">10.1086/500949</pub-id>
<?supplied-pmid 16544248?><pub-id pub-id-type="pmid">16544248</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1091393">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alcon-LePoder</surname><given-names>S</given-names></name><name><surname>Drouet</surname><given-names>MT</given-names></name><name><surname>Roux</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>The secreted form of dengue virus nonstructural protein NS1 is endocytosed by hepatocytes and accumulates in late endosomes: implications for viral infectivity.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2005</year>;<volume>79</volume>(<issue>17</issue>):<fpage>11403</fpage>&#x02013;<lpage>11</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.79.17.11403-11411.2005</pub-id>
<!--<pub-id pub-id-type="pmcid">1193635</pub-id>-->
<?supplied-pmid 16103191?><pub-id pub-id-type="pmid">16103191</pub-id></mixed-citation></ref><ref id="ref-92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>SW</given-names></name><name><surname>Chuang</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><etal/></person-group>:
<article-title>Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation.</article-title>
<source><italic toggle="yes">J Infect.</italic></source>
<year>2012</year>;<volume>64</volume>(<issue>3</issue>):<fpage>325</fpage>&#x02013;<lpage>34</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jinf.2011.11.023</pub-id>
<?supplied-pmid 22138554?><pub-id pub-id-type="pmid">22138554</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717959617">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chao</surname><given-names>CH</given-names></name><name><surname>Wu</surname><given-names>WC</given-names></name><name><surname>Lai</surname><given-names>YC</given-names></name><etal/></person-group>:
<article-title>Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage.</article-title>
<source><italic toggle="yes">PLoS Pathog.</italic></source>
<year>2019</year>;<volume>15</volume>(<issue>4</issue>):<fpage>e1007625</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.ppat.1007625</pub-id>
<!--<pub-id pub-id-type="pmcid">6497319</pub-id>-->
<?supplied-pmid 31009511?><pub-id pub-id-type="pmid">31009511</pub-id></mixed-citation></ref><ref id="ref-94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Modhiran</surname><given-names>N</given-names></name><name><surname>Watterson</surname><given-names>D</given-names></name><name><surname>Muller</surname><given-names>DA</given-names></name><etal/></person-group>:
<article-title>Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity.</article-title>
<source><italic toggle="yes">Sci Transl Med.</italic></source>
<year>2015</year>;<volume>7</volume>(<issue>304</issue>):<fpage>304ra142</fpage>.
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa3863</pub-id>
<?supplied-pmid 26355031?><pub-id pub-id-type="pmid">26355031</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725780362">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beatty</surname><given-names>PR</given-names></name><name><surname>Puerta-Guardo</surname><given-names>H</given-names></name><name><surname>Killingbeck</surname><given-names>SS</given-names></name><etal/></person-group>:
<article-title>Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination.</article-title>
<source><italic toggle="yes">Sci Transl Med.</italic></source>
<year>2015</year>;<volume>7</volume>(<issue>304</issue>):<fpage>304ra141</fpage>.
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa3787</pub-id>
<?supplied-pmid 26355030?><pub-id pub-id-type="pmid">26355030</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725780363">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Puerta-Guardo</surname><given-names>H</given-names></name><name><surname>Glasner</surname><given-names>DR</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name></person-group>:
<article-title>Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability.</article-title>
<source><italic toggle="yes">PLoS Pathog.</italic></source>
<year>2016</year>;<volume>12</volume>(<issue>7</issue>):<fpage>e1005738</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.ppat.1005738</pub-id>
<!--<pub-id pub-id-type="pmcid">4944995</pub-id>-->
<?supplied-pmid 27416066?><pub-id pub-id-type="pmid">27416066</pub-id></mixed-citation></ref><ref id="ref-97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suwarto</surname><given-names>S</given-names></name><name><surname>Sasmono</surname><given-names>RT</given-names></name><name><surname>Sinto</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>Association of Endothelial Glycocalyx and Tight and Adherens Junctions With Severity of Plasma Leakage in Dengue Infection.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2017</year>;<volume>215</volume>(<issue>6</issue>):<fpage>992</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jix041</pub-id>
<!--<pub-id pub-id-type="pmcid">5407050</pub-id>-->
<?supplied-pmid 28453844?><pub-id pub-id-type="pmid">28453844</pub-id></mixed-citation></ref><ref id="ref-98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>TH</given-names></name><name><surname>Alonso</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>LF</given-names></name><etal/></person-group>:
<article-title>Increased Serum Hyaluronic Acid and Heparan Sulfate in Dengue Fever: Association with Plasma Leakage and Disease Severity.</article-title>
<source><italic toggle="yes">Sci Rep.</italic></source>
<year>2017</year>;<volume>7</volume>: 46191.
<pub-id pub-id-type="doi">10.1038/srep46191</pub-id>
<!--<pub-id pub-id-type="pmcid">5385535</pub-id>-->
<?supplied-pmid 28393899?><pub-id pub-id-type="pmid">28393899</pub-id></mixed-citation></ref><ref id="ref-99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glasner</surname><given-names>DR</given-names></name><name><surname>Ratnasiri</surname><given-names>K</given-names></name><name><surname>Puerta-Guardo</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components.</article-title>
<source><italic toggle="yes">PLoS Pathog.</italic></source>
<year>2017</year>;<volume>13</volume>(<issue>11</issue>):<fpage>e1006673</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.ppat.1006673</pub-id>
<!--<pub-id pub-id-type="pmcid">5679539</pub-id>-->
<?supplied-pmid 29121099?><pub-id pub-id-type="pmid">29121099</pub-id></mixed-citation></ref><ref id="ref-100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Espinosa</surname><given-names>DA</given-names></name><name><surname>Beatty</surname><given-names>PR</given-names></name><name><surname>Reiner</surname><given-names>GL</given-names></name><etal/></person-group>:
<article-title>Cyclic Dinucleotide-Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses.</article-title>
<source><italic toggle="yes">J Immunol.</italic></source>
<year>2019</year>;<volume>202</volume>(<issue>4</issue>):<fpage>1153</fpage>&#x02013;<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.4049/jimmunol.1801323</pub-id>
<!--<pub-id pub-id-type="pmcid">6363872</pub-id>-->
<?supplied-pmid 30642979?><pub-id pub-id-type="pmid">30642979</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734864160">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friberg</surname><given-names>H</given-names></name><name><surname>Beaumier</surname><given-names>CM</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2018</year>;<volume>12</volume>(<issue>12</issue>):<fpage>e0006975</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0006975</pub-id>
<!--<pub-id pub-id-type="pmcid">6312351</pub-id>-->
<?supplied-pmid 30557313?><pub-id pub-id-type="pmid">30557313</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734650175">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hadinegoro</surname><given-names>SR</given-names></name><name><surname>Arredondo-Garc&#x000ed;a</surname><given-names>JL</given-names></name><name><surname>Capeding</surname><given-names>MR</given-names></name><etal/></person-group>:
<article-title>Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.</article-title>
<source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2015</year>;<volume>373</volume>(<issue>13</issue>):<fpage>1195</fpage>&#x02013;<lpage>206</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1506223</pub-id>
<?supplied-pmid 26214039?><pub-id pub-id-type="pmid">26214039</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725675017">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-103"><label>103</label><mixed-citation publication-type="journal">
<collab>WHO</collab>:
<article-title>Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 &#x02013; conclusions and recommendations.</article-title>
<source><italic toggle="yes">Wkly Epidemiol Rec.</italic></source>
<year>2016</year>;<volume>91</volume>(<issue>21</issue>):<fpage>266</fpage>&#x02013;<lpage>84</lpage>.
<?supplied-pmid 27236869?><pub-id pub-id-type="pmid">27236869</pub-id></mixed-citation></ref><ref id="ref-104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>EJM</given-names></name><name><surname>George</surname><given-names>JK</given-names></name><name><surname>Velasco</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.</article-title>
<source><italic toggle="yes">J Virol Methods.</italic></source>
<year>2018</year>;<volume>257</volume>:<fpage>48</fpage>&#x02013;<lpage>57</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jviromet.2018.03.007</pub-id>
<?supplied-pmid 29567514?><pub-id pub-id-type="pmid">29567514</pub-id></mixed-citation></ref><ref id="ref-105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sridhar</surname><given-names>S</given-names></name><name><surname>Luedtke</surname><given-names>A</given-names></name><name><surname>Langevin</surname><given-names>E</given-names></name><etal/></person-group>:
<article-title>Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.</article-title>
<source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2018</year>;<volume>379</volume>(<issue>4</issue>):<fpage>327</fpage>&#x02013;<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1800820</pub-id>
<?supplied-pmid 29897841?><pub-id pub-id-type="pmid">29897841</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/733444900">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-106"><label>106</label><mixed-citation publication-type="journal">
<collab>WHO</collab>:
<article-title>Dengue vaccine: WHO position paper - September 2018.</article-title>
<source><italic toggle="yes">Wkly Epidemiol Rec.</italic></source>
<year>2018</year>;<volume>93</volume>(<issue>36</issue>):<fpage>457</fpage>&#x02013;<lpage>76</lpage>.
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/wer/2018/wer9336/en/">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sabchareon</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>D</given-names></name><name><surname>Sirivichayakul</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.</article-title>
<source><italic toggle="yes">Lancet.</italic></source>
<year>2012</year>;<volume>380</volume>(<issue>9853</issue>):<fpage>1559</fpage>&#x02013;<lpage>67</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61428-7</pub-id>
<?supplied-pmid 22975340?><pub-id pub-id-type="pmid">22975340</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717958880">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Capeding</surname><given-names>MR</given-names></name><name><surname>Tran</surname><given-names>NH</given-names></name><name><surname>Hadinegoro</surname><given-names>SR</given-names></name><etal/></person-group>:
<article-title>Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.</article-title>
<source><italic toggle="yes">Lancet.</italic></source>
<year>2014</year>;<volume>384</volume>(<issue>9951</issue>):<fpage>1358</fpage>&#x02013;<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)61060-6</pub-id>
<?supplied-pmid 25018116?><pub-id pub-id-type="pmid">25018116</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718490847">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Villar</surname><given-names>L</given-names></name><name><surname>Dayan</surname><given-names>GH</given-names></name><name><surname>Arredondo-Garc&#x000ed;a</surname><given-names>JL</given-names></name><etal/></person-group>:
<article-title>Efficacy of a tetravalent dengue vaccine in children in Latin America.</article-title>
<source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2015</year>;<volume>372</volume>(<issue>2</issue>):<fpage>113</fpage>&#x02013;<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1411037</pub-id>
<?supplied-pmid 25365753?><pub-id pub-id-type="pmid">25365753</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725223589">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katzelnick</surname><given-names>LC</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name></person-group>,
<collab>Participants in the Summit on Dengue Immune Correlates of Protection</collab>:
<article-title>Immune correlates of protection for dengue: State of the art and research agenda.</article-title>
<source><italic toggle="yes">Vaccine.</italic></source>
<year>2017</year>;<volume>35</volume>(<issue>36</issue>):<fpage>4659</fpage>&#x02013;<lpage>69</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.07.045</pub-id>
<!--<pub-id pub-id-type="pmcid">5924688</pub-id>-->
<?supplied-pmid 28757058?><pub-id pub-id-type="pmid">28757058</pub-id></mixed-citation></ref><ref id="ref-111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raut</surname><given-names>R</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Tennekoon</surname><given-names>RN</given-names></name><etal/></person-group>:
<article-title>Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.</article-title>
<source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source>
<year>2019</year>;<volume>116</volume>(<issue>1</issue>):<fpage>227</fpage>&#x02013;<lpage>232</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1812055115</pub-id>
<!--<pub-id pub-id-type="pmcid">6320508</pub-id>-->
<?supplied-pmid 30518559?><pub-id pub-id-type="pmid">30518559</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734570068">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Juraska</surname><given-names>M</given-names></name><name><surname>Magaret</surname><given-names>CA</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.</article-title>
<source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source>
<year>2018</year>;<volume>115</volume>(<issue>36</issue>):<fpage>E8378</fpage>&#x02013;<lpage>E8387</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1714250115</pub-id>
<!--<pub-id pub-id-type="pmcid">6130398</pub-id>-->
<?supplied-pmid 30127007?><pub-id pub-id-type="pmid">30127007</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/733846869">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabaa</surname><given-names>MA</given-names></name><name><surname>Girerd-Chambaz</surname><given-names>Y</given-names></name><name><surname>Duong Thi Hue</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy.</article-title>
<source><italic toggle="yes">eLife.</italic></source>
<year>2017</year>;<volume>6</volume>: pii: e24196.
<pub-id pub-id-type="doi">10.7554/eLife.24196</pub-id>
<!--<pub-id pub-id-type="pmcid">5584992</pub-id>-->
<?supplied-pmid 28871961?><pub-id pub-id-type="pmid">28871961</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/730774201">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nivarthi</surname><given-names>UK</given-names></name><name><surname>Kose</surname><given-names>N</given-names></name><name><surname>Sapparapu</surname><given-names>G</given-names></name><etal/></person-group>:
<article-title>Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2017</year>;<volume>91</volume>(<issue>5</issue>): pii: e02041-16
<pub-id pub-id-type="doi">10.1128/JVI.02041-16</pub-id>
<!--<pub-id pub-id-type="pmcid">5309932</pub-id>-->
<?supplied-pmid 28031369?><pub-id pub-id-type="pmid">28031369</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727151660">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gallichotte</surname><given-names>EN</given-names></name><name><surname>Baric</surname><given-names>TJ</given-names></name><name><surname>Nivarthi</surname><given-names>U</given-names></name><etal/></person-group>:
<article-title>Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.</article-title>
<source><italic toggle="yes">Cell Rep.</italic></source>
<year>2018</year>;<volume>25</volume>(<issue>5</issue>):<fpage>1214</fpage>&#x02013;<lpage>1224</lpage>.
<pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.006</pub-id>
<!--<pub-id pub-id-type="pmcid">6226424</pub-id>-->
<?supplied-pmid 30380413?><pub-id pub-id-type="pmid">30380413</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734324212">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henein</surname><given-names>S</given-names></name><name><surname>Swanstrom</surname><given-names>J</given-names></name><name><surname>Byers</surname><given-names>AM</given-names></name><etal/></person-group>:
<article-title>Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2017</year>;<volume>215</volume>(<issue>3</issue>):<fpage>351</fpage>&#x02013;<lpage>358</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiw576</pub-id>
<!--<pub-id pub-id-type="pmcid">6392503</pub-id>-->
<?supplied-pmid 27932620?><pub-id pub-id-type="pmid">27932620</pub-id></mixed-citation></ref><ref id="ref-117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Bangs</surname><given-names>DJ</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Dengue virus infection elicits highly polarized CX3CR1
<sup>+</sup> cytotoxic CD4
<sup>+</sup> T cells associated with protective immunity.</article-title>
<source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source>
<year>2015</year>;<volume>112</volume>(<issue>31</issue>):<fpage>E4256</fpage>&#x02013;<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1505956112</pub-id>
<!--<pub-id pub-id-type="pmcid">4534238</pub-id>-->
<?supplied-pmid 26195744?><pub-id pub-id-type="pmid">26195744</pub-id></mixed-citation></ref><ref id="ref-118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Cerpas</surname><given-names>C</given-names></name><name><surname>Angelo</surname><given-names>MA</given-names></name><etal/></person-group>:
<article-title>Human CD8
<sup>+</sup> T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2015</year>;<volume>212</volume>(<issue>11</issue>):<fpage>1743</fpage>&#x02013;<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiv289</pub-id>
<!--<pub-id pub-id-type="pmcid">4633759</pub-id>-->
<?supplied-pmid 25980035?><pub-id pub-id-type="pmid">25980035</pub-id></mixed-citation></ref><ref id="ref-119"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elong Ngono</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Tang</surname><given-names>WW</given-names></name><etal/></person-group>:
<article-title>Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection.</article-title>
<source><italic toggle="yes">EBioMedicine.</italic></source>
<year>2016</year>;<volume>13</volume>:<fpage>284</fpage>&#x02013;<lpage>293</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.006</pub-id>
<!--<pub-id pub-id-type="pmcid">5264312</pub-id>-->
<?supplied-pmid 27746192?><pub-id pub-id-type="pmid">27746192</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726855627">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-120"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>Lopez</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Global Assessment of Dengue Virus-Specific CD4
<sup>+</sup> T Cell Responses in Dengue-Endemic Areas.</article-title>
<source><italic toggle="yes">Front Immunol.</italic></source>
<year>2017</year>;<volume>8</volume>:<fpage>1309</fpage>.
<pub-id pub-id-type="doi">10.3389/fimmu.2017.01309</pub-id>
<!--<pub-id pub-id-type="pmcid">5646259</pub-id>-->
<?supplied-pmid 29081779?><pub-id pub-id-type="pmid">29081779</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732052548">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-121"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name></person-group>:
<article-title>Cytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus Infection.</article-title>
<source><italic toggle="yes">Front Immunol.</italic></source>
<year>2016</year>;<volume>7</volume>:<fpage>531</fpage>.
<pub-id pub-id-type="doi">10.3389/fimmu.2016.00531</pub-id>
<!--<pub-id pub-id-type="pmcid">5141332</pub-id>-->
<?supplied-pmid 28003809?><pub-id pub-id-type="pmid">28003809</pub-id></mixed-citation></ref><ref id="ref-122"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>Bangs</surname><given-names>DJ</given-names></name><etal/></person-group>:
<article-title>The human CD8
<sup>+</sup> T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2015</year>;<volume>89</volume>(<issue>1</issue>):<fpage>120</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.02129-14</pub-id>
<!--<pub-id pub-id-type="pmcid">4301095</pub-id>-->
<?supplied-pmid 25320311?><pub-id pub-id-type="pmid">25320311</pub-id></mixed-citation></ref><ref id="ref-123"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angelo</surname><given-names>MA</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>O'Rourke</surname><given-names>PH</given-names></name><etal/></person-group>:
<article-title>Human CD4
<sup>+</sup> T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2017</year>;<volume>91</volume>(<issue>5</issue>): pii: e02147-16.
<pub-id pub-id-type="doi">10.1128/JVI.02147-16</pub-id>
<!--<pub-id pub-id-type="pmcid">5309943</pub-id>-->
<?supplied-pmid 27974563?><pub-id pub-id-type="pmid">27974563</pub-id></mixed-citation></ref><ref id="ref-124"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>JH</given-names></name><name><surname>Chua</surname><given-names>YL</given-names></name><name><surname>Lee</surname><given-names>PX</given-names></name><etal/></person-group>:
<article-title>Dengue vaccine-induced CD8
<sup>+</sup> T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.</article-title>
<source><italic toggle="yes">JCI Insight.</italic></source>
<year>2017</year>;<volume>2</volume>(<issue>24</issue>): pii: 94500.
<pub-id pub-id-type="doi">10.1172/jci.insight.94500</pub-id>
<!--<pub-id pub-id-type="pmcid">5752305</pub-id>-->
<?supplied-pmid 29263304?><pub-id pub-id-type="pmid">29263304</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732391295">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-125"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osorio</surname><given-names>JE</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Kinney</surname><given-names>RM</given-names></name><etal/></person-group>:
<article-title>Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.</article-title>
<source><italic toggle="yes">Vaccine.</italic></source>
<year>2011</year>;<volume>29</volume>(<issue>42</issue>):<fpage>7251</fpage>&#x02013;<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.020</pub-id>
<!--<pub-id pub-id-type="pmcid">4592106</pub-id>-->
<?supplied-pmid 21777638?><pub-id pub-id-type="pmid">21777638</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/13235956">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-126"><label>126</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osorio</surname><given-names>JE</given-names></name><name><surname>Velez</surname><given-names>ID</given-names></name><name><surname>Thomson</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.</article-title>
<source><italic toggle="yes">Lancet Infect Dis.</italic></source>
<year>2014</year>;<volume>14</volume>(<issue>9</issue>):<fpage>830</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/S1473-3099(14)70811-4</pub-id>
<!--<pub-id pub-id-type="pmcid">4648257</pub-id>-->
<?supplied-pmid 25087476?><pub-id pub-id-type="pmid">25087476</pub-id></mixed-citation></ref><ref id="ref-127"><label>127</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rupp</surname><given-names>R</given-names></name><name><surname>Luckasen</surname><given-names>GJ</given-names></name><name><surname>Kirstein</surname><given-names>JL</given-names></name><etal/></person-group>:
<article-title>Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.</article-title>
<source><italic toggle="yes">Vaccine.</italic></source>
<year>2015</year>;<volume>33</volume>(<issue>46</issue>):<fpage>6351</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.008</pub-id>
<?supplied-pmid 26384447?><pub-id pub-id-type="pmid">26384447</pub-id></mixed-citation></ref><ref id="ref-128"><label>128</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osorio</surname><given-names>JE</given-names></name><name><surname>Wallace</surname><given-names>D</given-names></name><name><surname>Stinchcomb</surname><given-names>DT</given-names></name></person-group>:
<article-title>A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.</article-title>
<source><italic toggle="yes">Expert Rev Vaccines.</italic></source>
<year>2016</year>;<volume>15</volume>(<issue>4</issue>):<fpage>497</fpage>&#x02013;<lpage>508</lpage>.
<pub-id pub-id-type="doi">10.1586/14760584.2016.1128328</pub-id>
<?supplied-pmid 26635182?><pub-id pub-id-type="pmid">26635182</pub-id></mixed-citation></ref><ref id="ref-129"><label>129</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Butrapet</surname><given-names>S</given-names></name><name><surname>Pierro</surname><given-names>DJ</given-names></name><etal/></person-group>:
<article-title>Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2000</year>;<volume>74</volume>(<issue>7</issue>):<fpage>3020</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1128/jvi.74.7.3020-3028.2000</pub-id>
<!--<pub-id pub-id-type="pmcid">111800</pub-id>-->
<?supplied-pmid 10708416?><pub-id pub-id-type="pmid">10708416</pub-id></mixed-citation></ref><ref id="ref-130"><label>130</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Kinney</surname><given-names>RM</given-names></name><name><surname>Livengood</surname><given-names>JA</given-names></name><etal/></person-group>:
<article-title>Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source>
<year>2013</year>;<volume>7</volume>(<issue>5</issue>):<fpage>e2243</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0002243</pub-id>
<!--<pub-id pub-id-type="pmcid">3667780</pub-id>-->
<?supplied-pmid 23738026?><pub-id pub-id-type="pmid">23738026</pub-id></mixed-citation></ref><ref id="ref-131"><label>131</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>DW</given-names></name><name><surname>Hoke</surname><given-names>CH</given-names><suffix>Jr</suffix></name><name><surname>Yoksan</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.</article-title>
<source><italic toggle="yes">Vaccine.</italic></source>
<year>1996</year>;<volume>14</volume>(<issue>4</issue>):<fpage>329</fpage>&#x02013;<lpage>36</lpage>.
<pub-id pub-id-type="doi">10.1016/0264-410X(95)00167-Y</pub-id>
<?supplied-pmid 8744561?><pub-id pub-id-type="pmid">8744561</pub-id></mixed-citation></ref><ref id="ref-132"><label>132</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butrapet</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Pierro</surname><given-names>DJ</given-names></name><etal/></person-group>:
<article-title>Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2000</year>;<volume>74</volume>(<issue>7</issue>):<fpage>3011</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1128/jvi.74.7.3011-3019.2000</pub-id>
<!--<pub-id pub-id-type="pmcid">111799</pub-id>-->
<?supplied-pmid 10708415?><pub-id pub-id-type="pmid">10708415</pub-id></mixed-citation></ref><ref id="ref-133"><label>133</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kinney</surname><given-names>RM</given-names></name><name><surname>Butrapet</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>GJ</given-names></name><etal/></person-group>:
<article-title>Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.</article-title>
<source><italic toggle="yes">Virology.</italic></source>
<year>1997</year>;<volume>230</volume>(<issue>2</issue>):<fpage>300</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1006/viro.1997.8500</pub-id>
<?supplied-pmid 9143286?><pub-id pub-id-type="pmid">9143286</pub-id></mixed-citation></ref><ref id="ref-134"><label>134</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Whitehead</surname><given-names>SS</given-names></name></person-group>:
<article-title>Next-generation dengue vaccines: novel strategies currently under development.</article-title>
<source><italic toggle="yes">Viruses.</italic></source>
<year>2011</year>;<volume>3</volume>(<issue>10</issue>):<fpage>1800</fpage>&#x02013;<lpage>14</lpage>.
<pub-id pub-id-type="doi">10.3390/v3101800</pub-id>
<!--<pub-id pub-id-type="pmcid">3205382</pub-id>-->
<?supplied-pmid 22069516?><pub-id pub-id-type="pmid">22069516</pub-id></mixed-citation></ref><ref id="ref-135"><label>135</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>SS</given-names></name></person-group>:
<article-title>Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD&#x02122; vaccine?</article-title>
<source><italic toggle="yes">Expert Rev Vaccines.</italic></source>
<year>2016</year>;<volume>15</volume>(<issue>4</issue>):<fpage>509</fpage>&#x02013;<lpage>17</lpage>.
<pub-id pub-id-type="doi">10.1586/14760584.2016.1115727</pub-id>
<!--<pub-id pub-id-type="pmcid">4956407</pub-id>-->
<?supplied-pmid 26559731?><pub-id pub-id-type="pmid">26559731</pub-id></mixed-citation></ref><ref id="ref-136"><label>136</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Kirkpatrick</surname><given-names>BD</given-names></name><name><surname>Pierce</surname><given-names>KK</given-names></name><etal/></person-group>:
<article-title>A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2013</year>;<volume>207</volume>(<issue>6</issue>):<fpage>957</fpage>&#x02013;<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jis936</pub-id>
<!--<pub-id pub-id-type="pmcid">3571448</pub-id>-->
<?supplied-pmid 23329850?><pub-id pub-id-type="pmid">23329850</pub-id></mixed-citation></ref><ref id="ref-137"><label>137</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>BD</given-names></name><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Pierce</surname><given-names>KK</given-names></name><etal/></person-group>:
<article-title>Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2015</year>;<volume>212</volume>(<issue>5</issue>):<fpage>702</fpage>&#x02013;<lpage>10</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiv082</pub-id>
<!--<pub-id pub-id-type="pmcid">4612392</pub-id>-->
<?supplied-pmid 25801652?><pub-id pub-id-type="pmid">25801652</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725402172">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-138"><label>138</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>BD</given-names></name><name><surname>Whitehead</surname><given-names>SS</given-names></name><name><surname>Pierce</surname><given-names>KK</given-names></name><etal/></person-group>:
<article-title>The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.</article-title>
<source><italic toggle="yes">Sci Transl Med.</italic></source>
<year>2016</year>;<volume>8</volume>(<issue>330</issue>):<fpage>330ra36</fpage>.
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaf1517</pub-id>
<?supplied-pmid 27089205?><pub-id pub-id-type="pmid">27089205</pub-id></mixed-citation></ref><ref id="ref-139"><label>139</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Kirkpatrick</surname><given-names>BD</given-names></name><name><surname>Pierce</surname><given-names>KK</given-names></name><etal/></person-group>:
<article-title>A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2016</year>;<volume>214</volume>(<issue>6</issue>):<fpage>832</fpage>&#x02013;<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiw067</pub-id>
<!--<pub-id pub-id-type="pmcid">4996143</pub-id>-->
<?supplied-pmid 26908742?><pub-id pub-id-type="pmid">26908742</pub-id></mixed-citation></ref><ref id="ref-140"><label>140</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>de Alwis</surname><given-names>R</given-names></name><name><surname>Kose</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2013</year>;<volume>207</volume>(<issue>12</issue>):<fpage>1898</fpage>&#x02013;<lpage>908</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jit119</pub-id>
<!--<pub-id pub-id-type="pmcid">3654755</pub-id>-->
<?supplied-pmid 23526830?><pub-id pub-id-type="pmid">23526830</pub-id></mixed-citation><note><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717991828">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-141"><label>141</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsai</surname><given-names>WY</given-names></name><name><surname>Durbin</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>JJ</given-names></name><etal/></person-group>:
<article-title>Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.</article-title>
<source><italic toggle="yes">J Virol.</italic></source>
<year>2015</year>;<volume>89</volume>(<issue>14</issue>):<fpage>7348</fpage>&#x02013;<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.00273-15</pub-id>
<!--<pub-id pub-id-type="pmcid">4473561</pub-id>-->
<?supplied-pmid 25972550?><pub-id pub-id-type="pmid">25972550</pub-id></mixed-citation></ref><ref id="ref-142"><label>142</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swanstrom</surname><given-names>JA</given-names></name><name><surname>Nivarthi</surname><given-names>UK</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2019</year>;<volume>220</volume>(<issue>2</issue>):<fpage>219</fpage>&#x02013;<lpage>27</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiz109</pub-id>
<!--<pub-id pub-id-type="pmcid">6581895</pub-id>-->
<?supplied-pmid 30895307?><pub-id pub-id-type="pmid">30895307</pub-id></mixed-citation></ref><ref id="ref-143"><label>143</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopes</surname><given-names>TRR</given-names></name><name><surname>Silva</surname><given-names>CS</given-names></name><name><surname>Pastor</surname><given-names>AF</given-names></name><etal/></person-group>:
<article-title>Dengue in Brazil in 2017: what happened?</article-title>
<source><italic toggle="yes">Rev Inst Med Trop Sao Paulo.</italic></source>
<year>2018</year>;<volume>60</volume>:<fpage>e43</fpage>.
<pub-id pub-id-type="doi">10.1590/S1678-9946201860043</pub-id>
<!--<pub-id pub-id-type="pmcid">6103327</pub-id>-->
<?supplied-pmid 30133603?><pub-id pub-id-type="pmid">30133603</pub-id></mixed-citation></ref></ref-list></back></article>